<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85898</article-id><article-id pub-id-type="doi">10.7554/eLife.85898</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-302912"><name><surname>Farmaki</surname><given-names>Elena</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5038-5875</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208112"><name><surname>Nath</surname><given-names>Aritro</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302267"><name><surname>Emond</surname><given-names>Rena</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302913"><name><surname>Karimi</surname><given-names>Kimya L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302914"><name><surname>Grolmusz</surname><given-names>Vince K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302915"><name><surname>Cosgrove</surname><given-names>Patrick A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7784-7785</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-116338"><name><surname>Bild</surname><given-names>Andrea H</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4850-0453</contrib-id><email>abild@coh.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00w6g5w60</institution-id><institution>Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Duarte</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Yang</surname><given-names>Yongliang</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/023hj5876</institution-id><institution>Dalian University of Technology</institution></institution-wrap><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032d4f246</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>29</day><month>09</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e85898</elocation-id><history><date date-type="received" iso-8601-date="2022-12-30"><day>30</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-08-17"><day>17</day><month>08</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-12-27"><day>27</day><month>12</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.12.27.522019"/></event></pub-history><permissions><copyright-statement>Â© 2023, Farmaki et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Farmaki et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85898-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-85898-figures-v1.pdf"/><abstract><p>The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ breast cancer (BC). However, most patients develop resistance and progress on therapy, highlighting the need to discover strategies that increase mTOR inhibitor effectiveness. We developed ER+ BC cell lines, sensitive or resistant to everolimus, and discovered that combination treatment of ONC201/TIC10 with everolimus inhibited cell growth in 2D/3D in vitro studies. We confirmed increased therapeutic response in primary patient cells progressing on everolimus, supporting clinical relevance. We show that ONC201/TIC10 mechanism in metastatic ER+ BC cells involves oxidative phosphorylation inhibition and stress response activation. Transcriptomic analysis in everolimus resistant breast patient tumors and mitochondrial functional assays in resistant cell lines demonstrated increased mitochondrial respiration dependency, contributing to ONC201/TIC10 sensitivity. We propose that ONC201/TIC10 and modulation of mitochondrial function may provide an effective add-on therapy strategy for patients with metastatic ER+ BCs resistant to mTOR inhibitors.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Breast cancer is one of the most frequently diagnosed cancers globally, particularly among women. The most common type of breast cancer expresses a receptor for the hormone estrogen. Many treatments block the activity of estrogen and therefore slow or block the development and spread of this type of breast cancer.</p><p>For patients with advanced breast cancer, hormone-blocking treatments work best in combination with other drugs, including one called everolimus. However, in many patients the cancer cells become resistant to these therapies, leading to disease progression and decreased survival.</p><p>To explore treatment strategies that could enhance the effectiveness of existing therapies for breast cancer, Farmaki et al. studied how cancer cells which had become resistant to everolimus responded when treated with an experimental drug called ONC201/TIC10.</p><p>A combination of everolimus and ONC201/TIC10 inhibited growth of resistant cancer cells that had been grown in a three-dimensional arrangement to mimic human tumors. Moreover, the drug combination effectively targeted breast cancer cells collected from patients whose cancer had progressed while being treated with everolimus, suggesting that ONC201/TIC10 could be relevant in a clinical setting. Finally, molecular and biochemical experiments revealed that the drug ONC201/TIC10 works by disrupting the pathways that everolimus-resistant cancer cells use to generate the energy required to grow and proliferate.</p><p>Taken together these findings suggest that ONC201/TIC10 may provide an effective add-on therapy for patients with certain types of advanced breast cancer that are no longer responding to everolimus. Before this becomes a reality for patients, however, there will have to be more experimental testing of ONC201/TIC10 to determine optimal dosing and timing strategy for future clinical trials.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>breast cancer</kwd><kwd>drug resistance</kwd><kwd>everolimus</kwd><kwd>ONC201/TIC10</kwd><kwd>mitochondria</kwd><kwd>stress response</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>U01CA264620</award-id><principal-award-recipient><name><surname>Bild</surname><given-names>Andrea H</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>U54CA209978</award-id><principal-award-recipient><name><surname>Bild</surname><given-names>Andrea H</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Experimental and clinical models identify an effective add-on therapy for drug resistant estrogen receptor positive advanced breast cancer.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Breast cancer (BC) is a fatal disease with 287,850 new cases in 2022 in the United States and an estimated mortality rate of 43,250 (<ext-link ext-link-type="uri" xlink:href="https://seer.cancer.gov/statfacts/html/breast.html">https://seer.cancer.gov/statfacts/html/breast.html</ext-link>). The most common BC subtype is positive for hormone receptor (HR+) and does not overexpress the human epidermal growth factor receptor 2 (HER2/neu), accounting for 68% of all BC cases (<ext-link ext-link-type="uri" xlink:href="https://seer.cancer.gov/statfacts/html/breast-subtypes.html">https://seer.cancer.gov/statfacts/html/breast-subtypes.html</ext-link>). The primary treatment for estrogen receptor positive (ER+), HER2â BC are therapies targeting estrogen signaling; however, resistance to these therapies in metastatic BC (mBC) and disease progression remains a significant challenge (<xref ref-type="bibr" rid="bib48">Osborne and Schiff, 2011</xref>).</p><p>Aberrant activation of the mammalian (mechanistic) target of rapamycin (mTOR) signaling has been identified in multiple human tumors (<xref ref-type="bibr" rid="bib20">Hare and Harvey, 2017</xref>; <xref ref-type="bibr" rid="bib47">Ortolani et al., 2015</xref>) and is involved in resistance to endocrine therapy (<xref ref-type="bibr" rid="bib29">Johnston, 2015</xref>; <xref ref-type="bibr" rid="bib48">Osborne and Schiff, 2011</xref>). Everolimus, an analog of rapamycin, binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that inhibits the activation of mTOR, a key regulatory kinase (<xref ref-type="bibr" rid="bib13">Faivre et al., 2006</xref>; <xref ref-type="bibr" rid="bib34">Law et al., 2006</xref>; <xref ref-type="bibr" rid="bib43">Mita et al., 2003</xref>). Everolimus in combination with the aromatase inhibitor exemestane improved progression-free survival in patients with advanced BC (<xref ref-type="bibr" rid="bib3">Baselga et al., 2012</xref>). Based on these clinical studies the combination was approved in 2012 as a second-line therapy for recurrent or mBC (National Comprehensive Cancer Network, NCCN guidelines) (<xref ref-type="bibr" rid="bib3">Baselga et al., 2012</xref>). Despite its efficacy, a large subset of patients develops progression and resistance to this combination, highlighting the need for more effective therapeutic strategies for advanced BC.</p><p>Studies on everolimus resistance in BC revealed survival mechanisms including activation of Protein kinase B family (AKT) (<xref ref-type="bibr" rid="bib7">Carew et al., 2011</xref>; <xref ref-type="bibr" rid="bib8">Chen et al., 2013</xref>) and Mitogen-activated protein kinase (MAPK) signaling (<xref ref-type="bibr" rid="bib6">Campone et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Carew et al., 2011</xref>; <xref ref-type="bibr" rid="bib30">Kimura et al., 2018</xref>; <xref ref-type="bibr" rid="bib41">Mendoza et al., 2011</xref>), upregulation of MYC (<xref ref-type="bibr" rid="bib4">Bihani et al., 2015</xref>; <xref ref-type="bibr" rid="bib38">Lui et al., 2016</xref>), increased oxidative stress (<xref ref-type="bibr" rid="bib46">Neklesa and Davis, 2008</xref>), metabolic reprogramming (<xref ref-type="bibr" rid="bib51">Pusapati et al., 2016</xref>), increased expression of anti-apoptotic molecules such as survivin (<xref ref-type="bibr" rid="bib58">Taglieri et al., 2017</xref>), and activation of epithelial and mesenchymal transition (<xref ref-type="bibr" rid="bib21">Holder et al., 2015</xref>).</p><p>ONC201/TIC10 belongs to the imipridone class of inhibitors and is currently being evaluated in clinical trials for solid tumors including breast and endometrial cancer, gliomas, and hematological malignancies (<xref ref-type="bibr" rid="bib49">Prabhu et al., 2020</xref>). The mechanism of ONC201/TIC10 action involves binding and activation of the mitochondrial protease caseinolytic protease P (ClpP) (<xref ref-type="bibr" rid="bib17">Greer et al., 2022</xref>; <xref ref-type="bibr" rid="bib27">Jacques et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Graves et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Ishizawa et al., 2019</xref>) and inhibition of the G-protein-coupled receptor (GPCR) dopamine receptor D2 (DRD2) (<xref ref-type="bibr" rid="bib32">Kline et al., 2018</xref>). ONC201/TIC10 has been shown to synergize with everolimus in prostate cancer (<xref ref-type="bibr" rid="bib35">Lev et al., 2018</xref>). Furthermore, colorectal cancer cells were more sensitive to the combination of ONC201/TIC10 with mTOR inhibitor AZD-8055 (<xref ref-type="bibr" rid="bib28">Jin et al., 2016</xref>). While the effectiveness of the combination of everolimus with ONC201/TIC10 has not been studied in BC, upregulation of mitochondrial ClpP that is a target of ONC201/TIC10 has been reported both in BC cells and tissues (<xref ref-type="bibr" rid="bib9">Cormio et al., 2021</xref>; <xref ref-type="bibr" rid="bib39">Luo et al., 2020</xref>). In addition, ONC201/TIC10 inhibits mitochondrial oxidative phosphorylation in BC cells, causing depletion of cellular ATP (<xref ref-type="bibr" rid="bib11">Dwucet et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Greer et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Ishida et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Pruss et al., 2020</xref>). Increased dependency on oxidative phosphorylation (OXPHOS) has been shown in chemotherapy resistant triple negative BC (<xref ref-type="bibr" rid="bib12">Evans et al., 2021</xref>). Therefore, targeting ClpP and mitochondrial metabolism could constitute a valid approach for increasing the efficacy of everolimus.</p><p>The aim of our study was to explore treatment strategies that can enhance the anti-tumor activity of standard of care therapy by targeting common resistant states specific to ER+ mBC. For our study, we developed in vitro models of acquired everolimus resistance for paired ER+ BC cell lines that are either sensitive or resistant to everolimus, and viable primary patient ER+ BC cells with known response to everolimus therapy. We used these models to identify therapies effective in everolimus resistant cancer cells and found that the small molecule ONC201/TIC10 can inhibit the proliferation of resistant cells by disrupting mitochondrial function and metabolism. RNA-sequencing analysis in ER+ mBC tumors non-responsive to everolimus and mitochondrial functional assays in resistant cell lines demonstrated increased dependency on mitochondrial respiration, further supporting the sensitivity to ONC201/TIC10. Thus, we demonstrate that ONC201/TIC10 enhances the durability of everolimus in resistant ER+ BC cell lines as well as primary cells from patients progressing on everolimus.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>ONC201/TIC10 inhibits the proliferation of BC cell lines sensitive and resistant to everolimus</title><p>Everolimus resistant cell lines were generated by long-term culture of parental cell lines in the continuous presence of 100 nM everolimus for MCF7 and T47D or 50 nM everolimus for CAMA-1 for 6â12 months (<xref ref-type="bibr" rid="bib40">McDermott et al., 2014</xref>). Parental untreated cell lines were maintained in culture for the same time as the everolimus-treated cell lines as paired everolimus sensitive cell lines. To quantify the extent of resistance, we performed doseâresponse assays with increasing concentrations of everolimus in sensitive and everolimus resistant cells. Resistant cells showed a statistically significant reduced response to everolimus compared to sensitive cells (p &lt; 0.05 for all paired cell lines, <xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>ONC201/TIC10 inhibits the proliferation of everolimus sensitive and resistant cells in 2D.</title><p>(<bold>A</bold>) Doseâresponse curves of CAMA-1, MCF7, and T47D everolimus sensitive and resistant cells under everolimus treatment. Cells were treated with increasing concentration of everolimus for 4 days and viability was measured using CellTiterGlo Chemiluminescent kit. (<bold>B</bold>) Cell viability after 4 days treatment with Dimethyl sulfoxide (DMSO), everolimus, ONC201/TIC10, or combination at the indicated concentrations. Data represent % viable cells compared with DMSO control treatment for each cell line and are shown as average of four replicates Â± standard deviation (SD). **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001. (<bold>C</bold>) Analysis of ONC201/TIC10 and everolimus interactions in 2D. Cells were treated with 1 nM everolimus (CAMA-1 and T47D) or 100 nM everolimus (MCF7), ONC201/TIC10, or combination at the indicated concentrations for 4 days in 2D and viability was measured using CellTiterGlo Chemiluminescent kit. The average Bliss Interaction Index was calculated and plotted as a heatmap in which red represents synergy and blue represents additivity.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85898-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title>ONC201/TIC10 inhibits the proliferation of everolimus sensitive and resistant cells in 2D.</title><p>Doseâresponse curves of CAMA-1, MCF7, and T47D everolimus sensitive and resistant cells under ONC201/TIC10 treatment. Cells were treated with increasing concentration of ONC201/TIC10 for 4 days and viability was measured using CellTiterGlo Chemiluminescent kit. Data represent % viable cells compared with DMSO control treatment for each cell line and are shown as average of four replicates Â± standard deviation (SD).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85898-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Next, we assessed the anti-proliferative efficacy of ONC201/TIC10 in the everolimus sensitive and resistant cell lines using both two-dimensional (2D) and three-dimensional (3D) assays. Sensitive and resistant cells were labeled with lentivirus to express a fluorescent protein for monitoring each populationâs growth when cultured (Venus and mCherry fluorescence for the sensitive and resistant cells, respectively). For the 2D assays, everolimus sensitive and resistant cells were treated with everolimus, ONC201/TIC10, or combination for 4 days. For the 3D assays, everolimus sensitive or resistant spheroids were cultured in the presence of drug treatments for 18 days with media and drug replacement every 3â4 days. Images and fluorescence signal intensity measurements were also captured on days of media and drug replacement to monitor growth inhibition over time.</p><p>In the 2D assays, ONC201/TIC10 single agent inhibited the proliferation of CAMA-1, MCF7, and T47D sensitive and resistant cells in a dose-dependent manner with IC50 values ranging from 1.43 to 1.90 ÂµM (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>). ONC201/TIC10 single agent treatment resulted in significant growth inhibition compared to control and everolimus single agent in all the resistant cell lines and in the CAMA-1 and MCF7 sensitive cells (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Combination of ONC201/TIC10 with everolimus significantly decreased cell proliferation compared to ONC201/TIC10 single agent, in all the resistant cell lines and in the MCF7 and T47D sensitive cells, by approximately 3% decrease for CAMA-1 sensitive, 5.5% for CAMA-1 resistant, 8% for MCF7 sensitive, 5% for MCF7 resistant, 8.8% for T74D sensitive, and 4.7% for T47D resistant (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Analysis of the drug interactions using the Bliss Interaction Index showed additive effect in all sensitive cell lines and T47D resistant cells and synergistic effect in the CAMA-1 and MCF7 resistant cells (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><p>In the 3D assays, ONC201/TIC10 single agent treatment resulted in significant growth inhibition compared to control in the all the resistant cell lines and in the T47D sensitive cells as indicated by the fluorescence intensity (<xref ref-type="fig" rid="fig2">Figure 2A, B</xref>). Even though everolimus single agent had increased inhibitory effect compared to ONC201/TIC10 single agent, the combination significantly inhibited spheroid growth in sensitive and resistant cell lines compared to both everolimus and ONC201/TIC10 single agent (<xref ref-type="fig" rid="fig2">Figure 2A, B</xref>). Drug interactions analysis showed moderately better than additive effect in the CAMA-1 resistant cells as well as in T47D sensitive and resistant cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Combination of ONC201/TIC10 and everolimus inhibits spheroid growth in 3D.</title><p>(<bold>A</bold>) Representative images of spheroid growth of sensitive (Venus, green) or resistant (mCherry, red) cells cultured in everolimus, ONC201/TIC10, or combination treated media at the indicated concentrations for up to 18 days. (<bold>B</bold>) Fluorescence intensity of sensitive and resistant cells under various treatment conditions. Data are represented as average of three replicates Â± standard deviation (SD). *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001. (<bold>C</bold>) Analysis of ONC201/TIC10 and everolimus interactions in 3D. Spheroids were cultured in the presence of drug treatments for 18 days and fluorescence intensity measurements were captured. The average Bliss Interaction Index was calculated and plotted as a heatmap in which red represents synergy and blue represents additivity.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85898-fig2-v1.tif"/></fig></sec><sec id="s2-2"><title>Combination therapy of ONC201/TIC10 and everolimus inhibits the growth of primary patient-derived ER+ BC cell spheroids</title><p>To further validate the effect of the combination of ONC201/TIC10 with everolimus in cells from patientsâ tumors, we performed 3D assays with primary cells from ascites or pleural effusion from patientsâ tumor samples. We used short-term experiments, compared to sensitive and resistant cell lines, since primary cells were more sensitive to the drug treatments. Patient samples were selected based on the treatment history, specifically refractory tumors from patients who had received hormonal therapy followed by several lines of treatment including everolimus and progressed (<xref ref-type="table" rid="table1">Table 1</xref>). Spheroids of patient-derived BC cells illustrate more accurately the characteristics of tumors in vivo and provide a more suitable model for the assessment of drug treatments compared with the 2D cultures (<xref ref-type="bibr" rid="bib23">Imamura et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Langhans, 2018</xref>). Spheroids from five different patients were treated with ONC201/TIC10, everolimus, or combination for 4 days. The effect of drug treatment on growth inhibition was assessed by measurement of cell proliferation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Our results indicate that combination therapy of ONC201/TIC10 with everolimus inhibits spheroid growth compared to everolimus single agent or ONC201/TIC10 single agent (ONC201/TIC10 single agent vs. combination 12.5% cell proliferation decrease for P1, 11% for P2, 4% for P3, 0.2% for P4, and 10.5% for P5) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Importantly, we compared the response of patientâs cells during everolimus treatment and after everolimus resistance, based on the availability of samples for P2 that were collected over the course of treatment. We used these two different tumor samples, from the same patient, during everolimus treatment or post-everolimus and during chemotherapy treatment (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). ONC201/TIC10 single agent or combination of ONC201/TIC10 with everolimus exhibited greater growth inhibition in the post-everolimus treatment cells (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>) as shown by the significant reduction in proliferation of these cells compared to the cells acquired during everolimus treatment (7.2% cell decrease in cell proliferation during everolimus vs. post-everolimus with ONC201/TIC10 and 9.2% cell decrease in cell proliferation during everolimus vs. post-everolimus with the combination) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) and decreased spheroid size (<xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>). These results highlight the efficacy of ONC201/TIC10 on the patient-derived resistant cells.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Combination therapy of ONC201/TIC10 and everolimus inhibits the growth of primary patient-derived cell spheroids.</title><p>(<bold>A</bold>) 3D cultures of primary patient-derived ER+ BC cells from ascites or pleural effusion treated with everolimus, ONC201/TIC10, or combination at the indicated concentrations for 4 days. Cell viability was measured using CellTiterGlo Chemiluminescent kit. (<bold>B</bold>) 3D cultures of primary patient-derived ER+ BC cells, while on everolimus treatment or post-everolimus treatment. Spheroids were treated with everolimus, ONC201/TIC10, or combination at the indicated concentrations for 4 days. Data represent % viable cells compared with DMSO control treatment and are shown as average of three replicates Â± standard deviation (SD). *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85898-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 1.</label><caption><title>Combination therapy of ONC201/TIC10 and everolimus inhibits the growth of primary patient-derived cell spheroids.</title><p>Representative images of spheroid growth of primary patient-derived ER+ BC cells collected during everolimus treatment or post-everolimus and therapy resistant, cultured and treated with everolimus, ONC201/TIC10, or combination at the indicated concentrations for 4 days.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85898-fig3-figsupp1-v1.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Treatment history of patients included in the study.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Patient diagnosis</th><th align="left" valign="bottom">Sample</th><th align="center" valign="bottom">Therapy lines</th><th align="center" valign="bottom">Drugs</th><th align="center" valign="bottom">Therapy lines post-everolimus</th></tr></thead><tbody><tr><td align="left" valign="bottom">P1</td><td align="left" valign="bottom">Metastatic ER+/HER2â</td><td align="left" valign="bottom">Ascites</td><td align="center" valign="bottom">6</td><td align="center" valign="bottom">12</td><td align="center" valign="bottom">2</td></tr><tr><td align="left" valign="bottom">P2</td><td align="left" valign="bottom">Metastatic ER+/PR+/HER2â</td><td align="left" valign="bottom">Ascites</td><td align="center" valign="bottom">7</td><td align="center" valign="bottom">9</td><td align="center" valign="bottom">2</td></tr><tr><td align="left" valign="bottom">P3</td><td align="left" valign="bottom">Metastatic ER+/PR+/HER2â</td><td align="left" valign="bottom">Pleural effusion</td><td align="center" valign="bottom">7</td><td align="center" valign="bottom">9</td><td align="center" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">P4</td><td align="left" valign="bottom">Metastatic ER+/PR+/HER2â</td><td align="left" valign="bottom">Ascites</td><td align="center" valign="bottom">10</td><td align="center" valign="bottom">14</td><td align="center" valign="bottom">5</td></tr><tr><td align="left" valign="bottom">P5</td><td align="left" valign="bottom">Metastatic ER+/PR+/HER2â</td><td align="left" valign="bottom">Ascites</td><td align="center" valign="bottom">5</td><td align="center" valign="bottom">6</td><td align="center" valign="bottom">1</td></tr></tbody></table></table-wrap></sec><sec id="s2-3"><title>ONC201/TIC10 causes loss of mitochondrial proteins and activation of stress response in everolimus sensitive and resistant cells</title><p>To identify the mechanism of ONC201/TIC10 sensitivity in the sensitive and resistant cells, we investigated the effects of the treatments on downstream signaling pathways, including mitochondrial pathways and stress pathways that have been previously described for BC cells under ONC201/TIC10 treatment (<xref ref-type="bibr" rid="bib16">Greer et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Ralff et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Yuan et al., 2017</xref>). Western blot analysis showed that ONC201/TIC10 suppresses the expression of the mitochondrial proteins TFAM (mitochondrial transcription factor A) and TUFM (translation elongation factor Tu) in all sensitive and resistant cell lines and specifically in a dose-dependent manner in CAMA-1 and T47D sensitive and resistant cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). TFAM and TUFM are important regulators of mitochondrial functions and are associated with the ONC201/TIC10-induced mitochondrial disruption (<xref ref-type="bibr" rid="bib15">Graves et al., 2019</xref>; <xref ref-type="bibr" rid="bib16">Greer et al., 2018</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>ONC201/TIC10 causes loss of mitochondrial proteins and activation of stress response in everolimus sensitive and resistant cells.</title><p>(<bold>A</bold>) CAMA-1, MCF7, T47D everolimus sensitive and resistant cells were treated for 24 hr with ONC201/TIC10 at the indicated concentrations, and cell lysates were immunoblotted for TUFM, TFAM, BiP, ATF4, CHOP, and OXPHOS complexes (Complex I subunit NDUFB8, Complex II subunit 30 kDa, Complex III subunit Core 2, Complex IV subunit II, and ATP synthase subunit alpha), and Î²-actin. Quantitation of TUFM, TFAM, BiP, ATF4, and CHOP using ImageJ analysis. Protein expression levels were normalized to Î²-actin and are shown as average of two replicates Â± standard deviation (SD). *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001. (<bold>B</bold>) CAMA-1, MCF7, T47D everolimus sensitive and resistant cells were treated for 24 hr with everolimus, ONC201/TIC10, and combination at the indicated concentrations, and cell lysates were immunoblotted for the same proteins as above.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4âsource data 1.</label><caption><title>Original files of the full blot images for <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85898-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4âsource data 2.</label><caption><title>Original files of the full blot images for <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85898-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4âsource data 3.</label><caption><title>Figures with uncropped blot images for <xref ref-type="fig" rid="fig4">Figure 4A, B</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-85898-fig4-data3-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85898-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 1.</label><caption><title>ONC201/TIC10 mechanism in everolimus sensitive and resistant cells is TRAIL independent.</title><p>CAMA-1, MCF7, T47D everolimus sensitive and resistant cells were treated for 24 hr with everolimus, ONC201/TIC10, and combination at the indicated concentrations. Cell lysates were immunoblotted for pAKT, AKT, pERK, ERK, pFoxO3a, FoxO3a, TRAIL, pS6, S6, and Î²-actin.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4âfigure supplement 1âsource data 1.</label><caption><title>Original files of the full blot images for <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85898-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4âfigure supplement 1âsource data 2.</label><caption><title>Figures with uncropped blot images for <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-85898-fig4-figsupp1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85898-fig4-figsupp1-v1.tif"/></fig></fig-group><p>We further assessed the effect of ONC201/TIC10 on the oxidative phosphorylation proteins since ONC201/TIC10 toxicity has been linked to impaired OXPHOS in breast and brain tumors (<xref ref-type="bibr" rid="bib11">Dwucet et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Greer et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Ishida et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Pruss et al., 2020</xref>). ONC201/TIC10 suppresses the expression of the respiratory chain complexes in sensitive and resistant cells, specifically Complex I subunit NDUFB8, Complex II subunit 30 kDa (CAMA-1 and MCF7), Complex III subunit Core 2, and ATP synthase subunit alpha (<xref ref-type="fig" rid="fig4">Figure 4A</xref>).</p><p>Next, we evaluated in our model the activation of the Integrated Stress Response (ISR), that has been reported to follow mitochondrial dysfunction in breast (<xref ref-type="bibr" rid="bib16">Greer et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Ralff et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Yuan et al., 2017</xref>) and other malignancies (<xref ref-type="bibr" rid="bib2">Al Madhoun et al., 2021</xref>; <xref ref-type="bibr" rid="bib14">Fan et al., 2022</xref>; <xref ref-type="bibr" rid="bib35">Lev et al., 2018</xref>). ONC201/TIC10 induces the expression of the chaperone BiP (HP70) in all sensitive cell lines, and specifically in a dose-dependent manner in CAMA-1 and T47D sensitive and resistant cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Furthermore, ONC201/TIC10 induces the expression of the transcription factor ATF4 in all sensitive and resistant cell lines, with a dose-dependent effect in CAMA-1 and T47D sensitive cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The transcription factor CHOP is induced after treatment in all sensitive and resistant cell lines, with a dose-dependent effect in MCF7 and T47D sensitive and resistant cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>).</p><p>Combination treatment of ONC201/TIC10 with everolimus had the same effect on the suppression of the mitochondrial proteins TFAM and TUFM and the OXPHOS complexes as the single agent (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Everolimus single agent did not affect the mitochondrial protein levels, as expected (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Activation of stress response was not observed with the combination in the sensitive cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><p>Inhibition of AKT, ERK, and FoxO3a phosphorylation and activation of TRAIL that were previously described for ONC201/TIC10 (<xref ref-type="bibr" rid="bib1">Allen et al., 2013</xref>; <xref ref-type="bibr" rid="bib52">Ralff et al., 2017</xref>) were not observed in our model system (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>). Furthermore, ONC201/TIC10 inhibits the phosphorylation of ribosomal protein S6 that is downstream of mTOR signaling and this inhibition is increased in the resistant cell lines (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>).</p><p>To corroborate the mechanism of ONC201/TIC10 action observed in our experiments, we analyzed time course gene expression data of the MDA-MB-231 BC cell line treated with ONC201/TIC10 (<xref ref-type="bibr" rid="bib16">Greer et al., 2018</xref>). Using a generalized linear model, we investigated the changes in pathway activity levels of the cell line measured at 0, 3, 6, 12, and 24 hr after treatment. Over the time course, ONC201/TIC10 treatment significantly reduced cell cycle pathway activity in the cell line (p = 1.8 Ã 10<sup>â6</sup>) (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Concurrently, we found a significant increase in the ATF4 target genes activated in response to ER stress (p = 1.2 Ã 10<sup>â4</sup>) (<xref ref-type="fig" rid="fig5">Figure 5B</xref>) and the UPR pathway activity (p = 1.8 Ã 10<sup>â4</sup>) (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). In contrast, neither of the ERK (p = 0.55) (<xref ref-type="fig" rid="fig5">Figure 5D</xref>) or AKT (p = 0.61) (<xref ref-type="fig" rid="fig5">Figure 5E</xref>) signaling pathways showed any change in activity over time.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Change in pathway activity over time in response to ONC201/TIC10.</title><p>Scatter plots displaying the enrichment scores (<italic>Y</italic>-axis) of (<bold>A</bold>) REACTOME cell cycle signature, (<bold>B</bold>) REACTOME ATF4 activated genes in response to endoplasmic reticulum stress signature, (<bold>C</bold>) REACTOME unfolded protein response UPR signature, (<bold>D</bold>) BIOCARTA ERK pathway signature, and (<bold>E</bold>) BIOCARTA AKT pathway signature over time (<italic>X</italic>-axis). The solid lines and shaded area indicate linear fit and 95% confidence intervals, respectively, with p-value of the fit indicated above each plot. The analysis includes data from six replicates at time 0 hr, and three replicates each at time 3, 6, 12, and 24 hr for a total <italic>n</italic> = 18.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85898-fig5-v1.tif"/></fig></sec><sec id="s2-4"><title>ONC201/TIC10 inhibits mitochondrial respiration in everolimus sensitive and resistant cells</title><p>Based on the findings for the mitochondrial pathways, we then assessed the mitochondrial respiratory capacity of sensitive and resistant cell lines using extracellular flux analysis. Comparison of the mitochondrial respiration between the sensitive and resistant cells indicates that CAMA-1 resistant cells have lower basal and maximal respiratory capacity compared to the sensitive cells while MCF7 and T47D resistant cells have significantly increased baseline, maximal and ATP-linked respiration compared to the sensitive cells suggesting increased dependency on OXPHOS for ATP production (<xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1</xref>). Furthermore, all resistant lines showed significantly increased baseline and stressed extracellular acidification rate (ECAR) (<xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1</xref>). Treatment with ONC201/TIC10 resulted in a significant decrease in oxidative consumption rates (OCR) compared to control and everolimus single agent, in both sensitive and resistant cell lines at baseline, maximal and ATP-linked respiration (<xref ref-type="fig" rid="fig6">Figure 6</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6âfigure supplement 2</xref>). In addition, combination treatment of ONC201/TIC10 with everolimus further reduced mitochondrial respiratory capacities in all sensitive and resistant cells, except CAMA-1 cells that ONC201/TIC10 alone has similar effect on OCR as the combination (<xref ref-type="fig" rid="fig6">Figure 6</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6âfigure supplement 2</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>ONC201/TIC10 inhibits mitochondrial respiration in everolimus sensitive and resistant cells.</title><p>Cells were treated for 18 hr with indicated concentrations of everolimus, ONC201/TIC10, and combination. Mitochondrial respiration was measured using Seahorse XF Cell Mito Stress assay and oxygen consumption rates (OCR) are shown. Values were normalized to cell number generated from fluorescence intensity measurements and are represented as average of three replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85898-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6âfigure supplement 1.</label><caption><title>Mitochondrial respiration in everolimus sensitive and resistant cells.</title><p>Cells were cultured for 18 hr. Mitochondrial respiration was measured using Seahorse XF Cell Mito Stress assay and oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) graphs are shown. Values were normalized to cell number generated from fluorescence intensity measurements and are represented as average of three replicates Â± standard deviation (SD). *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85898-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6âfigure supplement 2.</label><caption><title>ONC201/TIC10 inhibits mitochondrial respiration in everolimus sensitive and resistant cells.</title><p>Cells were treated for 18 hr with indicated concentrations of ONC201/TIC10 and everolimus. Mitochondrial respiration was measured using Seahorse XF Cell Mito Stress assay and oxygen consumption rates (OCR) bar graphs are shown for basal, maximal respiration and ATP production. Values were normalized to cell number generated from fluorescence intensity measurements and are represented as average of three replicates Â± standard deviation (SD). *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85898-fig6-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Tumors non-responsive to everolimus sustain mitochondrial oxidative phosphorylation activity</title><p>We compared the changes in pathway phenotypes of mTOR inhibitor sensitive and resistant tumors using gene expression data from a neoadjuvant clinical trial of ER+ BC patients receiving everolimus (<xref ref-type="bibr" rid="bib54">Sabine et al., 2010</xref>). We examined the changes in 21 patients by comparing single sample gene set enrichment scores of pathway signatures from the RNA-sequencing data from this trial taken before and after 11â14 days of treatment with everolimus. Patients classified as everolimus responders based on decrease in Ki67 staining post-treatment displayed significant decrease in cell cycle signature (p = 4.3 Ã 10<sup>â3</sup>), while non-responders did not show a significant change (p = 0.2) (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). This result confirmed that everolimus failed to control the growth and proliferation of resistant tumors in an independent patient dataset. In the responder group, we found that everolimus treatment led to a significant decrease in the mitochondrial oxidative phosphorylation (p = 7.6 Ã 10<sup>â3</sup>), while there was no significant difference in the non-respondersâ group (p = 0.83) (<xref ref-type="fig" rid="fig7">Figure 7B</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Cell cycle and oxidative phosphorylation pathway activity and neoadjuvant everolimus response.</title><p>Box plots comparing cell cycle pathway activity indicated by (<bold>A</bold>) REACTOME cell cycle signature enrichment scores and (<bold>B</bold>) Kyoto Encyclopedia of Genes and Genomes (KEGG) oxidative phosphorylation signature enrichment scores between pre- and post-treatment samples. The left panel shows patients that were classified as responders to everolimus, while the right panel shows patients that were classified as non-responders. Colored boxes indicate interquartile range, horizontal bars indicate median, and the whiskers indicate first and third quartiles. p-values from paired two-tailed <italic>t</italic>-test comparing pre-treatment vs. post-treatment scores are indicated above the plots.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85898-fig7-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Therapies targeting signaling pathways such as the CDK4/6 and the PI3K/AKT/mTOR pathway that have been identified among the pathways involved in endocrine therapy resistance (<xref ref-type="bibr" rid="bib29">Johnston, 2015</xref>) have provided a significant clinical benefit in ER+ BC. The BOLERO-2 study showed that addition of everolimus to exemestane significantly improves progression-free survival, in post-menopausal ER+ BCs from 2.8 months on exemestane alone to 6.9 months on everolimus plus exemestane (<xref ref-type="bibr" rid="bib3">Baselga et al., 2012</xref>). Despite this progress, resistance to targeted therapies still emerges in a substantial proportion of patients. Therefore, it is important to explore strategies to increase response to this therapy.</p><p>In the present study, we explored treatment strategies to improve targeted therapy response and survival by combining drugs targeting resistance mechanisms. Specifically, we investigated if combination of everolimus with ONC201/TIC10 is effective for resistant BC cells and could provide a promising treatment strategy. Previous studies showed the efficacy of ONC201/TIC10 in TNBC cells (<xref ref-type="bibr" rid="bib16">Greer et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Yuan et al., 2017</xref>). We focused on the effect of ONC201/TIC10 on advanced ER+ BC cells including everolimus resistant cells and patient-derived spheroids resistant to endocrine therapy and everolimus.</p><p>Our results show that non-responsive tumors continued to proliferate after everolimus treatment by utilizing oxidative phosphorylation pathway to fuel the growth of tumor cells and is consistent with the findings from the resistant cell lines, supporting that ONC201/TIC10 and modulation of mitochondrial function is effective in drug resistant cancer cells. Combination therapy with ONC201/TIC10 and everolimus showed increased growth inhibition in everolimus resistant BC cell lines as well as resistant patient tumor cells in 2D and 3D studies. In the 2D culture setting, ONC201/TIC10 was effective both as single agent and in combination with everolimus with similar potency in sensitive and resistant cells. In the 3D setting however, ONC201/TIC10 in combination with everolimus had a robust effect on growth inhibition in both resistant and sensitive cells, compared to ONC201/TIC10 single agent that had a minor effect. Differences in drug potency between the 2D and 3D cultures have been previously reported for BC cells and are associated with lower proliferation, increased apoptosis, microenvironmental conditions like hypoxia and reduced nutrients and altered signaling in the 3D setting (<xref ref-type="bibr" rid="bib5">Burdett et al., 2010</xref>; <xref ref-type="bibr" rid="bib19">Hamilton, 1998</xref>; <xref ref-type="bibr" rid="bib37">Lovitt et al., 2015</xref>). These differences highlight the importance of utilizing more than one experimental model based on the hypotheses that are being addressed and given the limitations of each. Consistent with the resistant cell lines, the combination therapy had increased anti-proliferative activity in the resistant patient-derived spheroids. Collectively, these results recapitulate the increased sensitivity to the combination therapy and further support clinical relevance.</p><p>Mechanistically, ONC201/TIC10 has been shown to directly activate ClpP, through various genetic and biochemical studies (<xref ref-type="bibr" rid="bib17">Greer et al., 2022</xref>; <xref ref-type="bibr" rid="bib27">Jacques et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Graves et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Ishizawa et al., 2019</xref>). In BC, silencing of ClpP using siRNA or CRISPR/Cas9 System confirmed the ClpP-dependent effects of ONC201/TIC10 (<xref ref-type="bibr" rid="bib15">Graves et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Greer et al., 2022</xref>). Based on these established findings, we detail the specific pathway components driving the therapeutic response of ONC201/TIC10 in everolimus sensitive and resistant cells. We show that ONC201/TIC10 causes mitochondrial dysfunction, which is consistent with previous findings for BC cells, including suppression of mitochondrial proteins, decreased OXPHOS and activation of stress response (<xref ref-type="bibr" rid="bib16">Greer et al., 2018</xref>). We observed this effect not only in the sensitive cells but also in everolimus resistant cells, which supports the similarity in potency of ONC201/TIC10 single agent in everolimus sensitive and resistant cells in 2D assays. Importantly, data from RNA-sequencing in everolimus resistant patient tumors and from mitochondrial functional assays in resistant cell lines demonstrated increased dependency on mitochondrial respiration supporting the sensitivity to ONC201/TIC10. Therefore, ONC201/TIC10 could be a suitable candidate for the treatment of everolimus resistant tumors that depend on mitochondrial oxidative phosphorylation activity for sustained growth and proliferation.</p><p>Combination of ONC201/TIC10 with everolimus maintained the same level of mitochondrial and OXPHOS protein suppression as ONC201/TIC10 single agent. However, the activation of ISR after combination treatment was maintained only in the everolimus resistant cells and not the sensitive. This result suggests that in the sensitive cells, everolimus alleviates endoplasmic reticulum stress through the activation of different cell death mechanisms. Together these findings support the increased sensitivity of the combination in everolimus resistant cells and suggest as a mechanism of anti-proliferative activity the disruption of mitochondria and activation of stress response. Furthermore, western blot analysis and gene expression data confirm that the observed activity of ONC201/TIC10 is via induction of mitochondrial stress rather than ERK/AKT inactivation. Increased gene expression and protein levels of pro-apoptotic transcription factors CHOP and ATF4 have been reported for ONC201/TIC10 treatment (<xref ref-type="bibr" rid="bib16">Greer et al., 2018</xref>; <xref ref-type="bibr" rid="bib25">Ishizawa et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Kline et al., 2016</xref>). Indeed, CHOP has been shown to induce apoptosis through the regulation of different anti- and pro-apoptotic genes, including genes encoding the Bcl-2 family proteins, GADD34, endoplasmic reticulum oxidoreductin 1 (ERO1Î±), Tribbles-related protein 3 (TRB3), and DOC (<xref ref-type="bibr" rid="bib22">Hu et al., 2018</xref>; <xref ref-type="bibr" rid="bib57">Szegezdi et al., 2006</xref>). In addition, CHOP can downregulate the expressions of Bcl-2, Bcl-xL, and Mcl-1, and upregulate the expression of BIM, causing increased BAK and BAX expression. Bcl-2, Bcl-xL, and Mcl-1 have been shown to be downregulated by imipridones and ONC201/TIC10 (<xref ref-type="bibr" rid="bib2">Al Madhoun et al., 2021</xref>; <xref ref-type="bibr" rid="bib53">Rumman et al., 2021</xref>; <xref ref-type="bibr" rid="bib56">Staley et al., 2021</xref>).</p><p>ATF4 can promote apoptosis either through regulating CHOP or independent of CHOP (<xref ref-type="bibr" rid="bib62">Wortel et al., 2017</xref>). ATF4 also downregulates the anti-apoptotic Bcl-2 protein and upregulates pro-apoptotic signaling through the proteins BIM, NOXA, and PUMA (<xref ref-type="bibr" rid="bib57">Szegezdi et al., 2006</xref>; <xref ref-type="bibr" rid="bib62">Wortel et al., 2017</xref>). ONC201/TIC10 caused apoptosis through ATF4 in lymphoma and leukemia cells and inhibited mTORC1 signaling through the upregulation of ATF4 and DDIT4 (<xref ref-type="bibr" rid="bib25">Ishizawa et al., 2016</xref>; <xref ref-type="bibr" rid="bib59">Wang and Dougan, 2019</xref>).</p><p>Our results show that ISR was not activated upon combination treatment with ONC201/TIC10 and everolimus in sensitive cells, suggesting that sensitivity to everolimus in these cells can result in the activation of cell death mechanisms bypassing ISR. In line with this assumption, mTOR inhibitors are known to induce apoptosis through decreasing expression levels of various anti-apoptotic proteins, including Bcl-2, Bcl-xL, Mcl-1, and survivin (<xref ref-type="bibr" rid="bib10">Du et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Mills et al., 2008</xref>; <xref ref-type="bibr" rid="bib60">Wangpaichitr et al., 2008</xref>). Other mechanisms of ONC201/TIC10 anti-proliferative activity in the everolimus resistant cells might include the involvement of c-Myc. High levels of c-Myc have been shown to be a predictive factor for growth inhibition and apoptosis by imipridones in glioblastoma (<xref ref-type="bibr" rid="bib24">Ishida et al., 2018</xref>). In addition, the role of the Myc gene in promoting mTOR inhibitor resistance has been described in ER+ BC (<xref ref-type="bibr" rid="bib4">Bihani et al., 2015</xref>).</p><p>In conclusion, we used preclinical and clinical models to characterize sensitivity to mTOR inhibition. Combining experimental and clinical patient-derived data with resistant cell line driven experiments, our study provides validated findings that are consistent across different contexts, thereby strengthening the potential for clinical applications of ONC201/TIC10. Collectively, our findings suggest that ONC201/TIC10 could be used as an add-on treatment after mTOR therapy progression. Based on the initial preclinical and clinical testing of ONC201/TIC10 that demonstrated benefit with a benign clinical profile, ONC201/TIC10 is being further evaluated as single agent or in combination with other cancer therapies for various tumor types (<xref ref-type="bibr" rid="bib49">Prabhu et al., 2020</xref>). Combination of ONC201/TIC10 with everolimus has been tested in an in vivo prostate model and was well tolerated, with no additional toxicity (<xref ref-type="bibr" rid="bib35">Lev et al., 2018</xref>). Further in vitro as well as in vivo testing of this combination would be necessary to determine the optimal dosing and timing strategy for future clinical trials.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>) female</td><td align="left" valign="bottom">CAMA-1 Breast; Mammary gland: adenocarcinoma</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-21</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>) female</td><td align="left" valign="bottom">MCF7 Breast; Mammary gland: adenocarcinoma epithelial cell</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-22</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>) female</td><td align="left" valign="bottom">T47D Breast; Mammary gland: carcinoma ductal epithelial cell</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-133</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>) female</td><td align="left" valign="bottom">Primary, P1, P2, P3, P4, P5</td><td align="left" valign="bottom">This paper. City of Hope IRB #07047 and #17334</td><td align="left" valign="bottom">P1, P2, P3, P4, P5</td><td align="left" valign="bottom">Pleural effusion or ascites samples from patients</td></tr><tr><td align="left" valign="bottom">Transfected construct (mammalian)</td><td align="left" valign="bottom">LeGO-V2 (Venus)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib61">Weber et al., 2008</xref> Addgene #27340</td><td align="left" valign="bottom">Addgene #27340; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_27340">Addgene_27340</ext-link></td><td align="left" valign="bottom">Lentiviral construct to<break/>transfect and express Venus fluorescent protein</td></tr><tr><td align="left" valign="bottom">Transfected construct (mammalian)</td><td align="left" valign="bottom">LeGO-C2 (mCherry)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib61">Weber et al., 2008</xref> Addgene #27339</td><td align="left" valign="bottom">Addgene #27339; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_27339">Addgene_27339</ext-link></td><td align="left" valign="bottom">Lentiviral construct to transfect and express mCherry fluorescent protein</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-BiP (C50B12) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#3177;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2119845">AB_2119845</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-pFoxO3a (Ser294) (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#5538; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10696878">AB_10696878</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-FoxO3a (D19A7) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#12829; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2636990">AB_2636990</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-pERK1/2 Thr202/Tyr204 (197G2) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#4377; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331775">AB_331775</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-ERK1/2 (137F5) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#4695; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_390779">AB_390779</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-pAKT Ser473 (D9E) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#4060; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2315049">AB_2315049</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-AKT (C67E7) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#4691; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_915783">AB_915783</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-pS6 Ser240/244 Ribosomal Protein (D68F8) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#5364; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10694233">AB_10694233</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-S6 Ribosomal Protein (54D2) (mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#2317; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2238583">AB_2238583</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Î²-actin (8H10D10) (mouse monoclonal) (HRP Conjugate)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#12262; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2566811">AB_2566811</ext-link></td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Î²-actin (13E5) (rabbit monoclonal) (HRP Conjugate)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#5125; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1903890">AB_1903890</ext-link></td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-rabbit IgG, HRP-linked (goat polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#7074; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2099233">AB_2099233</ext-link></td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-mouse IgG, HRP-linked (horse polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#7076; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330924">AB_330924</ext-link></td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-CREB-2/ATF-4 (B-3) (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#390063; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2810998">AB_2810998</ext-link></td><td align="left" valign="bottom">WB (1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-mtTFA (TFAM) (C-9) (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#376672; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11150497">AB_11150497</ext-link></td><td align="left" valign="bottom">WB (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-TRAIL (55B709.3) (mouse monoclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# MA1-41027; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1087999">AB_1087999</ext-link></td><td align="left" valign="bottom">WB (1.5 Î¼g/ml)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-CHOP (rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat#15204-1-AP; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2292610">AB_2292610</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-TUFM (rabbit polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat#PA5-27511; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2544987">AB_2544987</ext-link></td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Total OXPHOS (mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat#ab110411; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2756818">AB_2756818</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Everolimus (RAD001)</td><td align="left" valign="bottom">Selleckchem</td><td align="left" valign="bottom">Cat#S1120</td><td align="left" valign="bottom">Dissolved in DMSO</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ONC201/TIC10</td><td align="left" valign="bottom">Selleckchem</td><td align="left" valign="bottom">Cat#S7963</td><td align="left" valign="bottom">Dissolved in DMSO</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CellTiter-Glo Luminescent Cell Viability Assay</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat#G7573</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CellTiter-Glo 3D Cell Viability Assay</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat#G9682</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">EasySep CD45 Depletion Kit II</td><td align="left" valign="bottom">StemCell Technologies</td><td align="left" valign="bottom">Cat#17898</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">EasySep Dead Cell Removal (Annexin V) Kit</td><td align="left" valign="bottom">StemCell Technologies</td><td align="left" valign="bottom">Cat#17899</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Agilent Seahorse XF Cell Mito Stress Test Kit</td><td align="left" valign="bottom">Agilent Technologies</td><td align="left" valign="bottom">Cat#103015-100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">GraphPad Prism software</td><td align="left" valign="bottom">GraphPad (<ext-link ext-link-type="uri" xlink:href="https://graphpad.com">https://graphpad.com</ext-link>)</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom">Version 9.3.1</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Gen5 software</td><td align="left" valign="bottom">Biotek Instruments (<ext-link ext-link-type="uri" xlink:href="https://www.agilent.com/">https://www.agilent.com/</ext-link>)</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Version 3.05</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Seahorse Wave Desktop Software 2.6</td><td align="left" valign="bottom">Agilent Technologies (<ext-link ext-link-type="uri" xlink:href="https://www.agilent.com/">https://www.agilent.com/</ext-link>)</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014526">SCR_014526</ext-link></td><td align="left" valign="bottom">Version 2.6</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">ImageJ software</td><td align="left" valign="bottom">ImageJ (<ext-link ext-link-type="uri" xlink:href="http://imagej.nih.gov/ij/">http://imagej.nih.gov/ij/</ext-link>)</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003070">SCR_003070</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture and reagents</title><p>CAMA-1 (ATCC HTB-21) and MCF7 (ATCC HTB-22) human BC cell lines were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich #12306C) and antibioticâantimycotic solution. T47D (ATCC HTB-133) human BC cell line was maintained in RPMI supplemented with 10% FBS and antibioticâantimycotic solution. Cells were regularly tested for mycoplasma contamination using commercially available Mycoplasma detection kit (Myco Alert kit, Lonza). Cell lines were authenticated using STR profiling (Laragen, Inc). Everolimus (RAD001, #S1120) and ONC201/TIC10 (#S7963) were obtained from Selleckchem and dissolved in DMSO.</p><p>Everolimus resistant cell lines were generated by long-term culture of parental cell lines in the continuous presence of 100 nM everolimus (MCF7 and T47D) or 50 nM everolimus (CAMA-1) with fresh media and drug replenished every 3 days, until resistance developed (6â12 months). Resistance to everolimus was confirmed by the difference in the drug doseâresponse in comparison with the parental cells, measured using CellTiter-Glo Luminescent Cell Viability Assay (Promega Corporation #G7573). Everolimus resistant cells were further maintained in complete culture medium supplemented with 50 nM everolimus (CAMA-1) or 100 nM everolimus (MCF7 and T47D). Sensitive and resistant cells were labeled with Venus (LeGO-V2 Addgene #27340) and mCherry (LeGO-C2 Addgene #27339) fluorescent proteins, respectively, as described previously (<xref ref-type="bibr" rid="bib18">Grolmusz et al., 2020</xref>; <xref ref-type="bibr" rid="bib61">Weber et al., 2008</xref>).</p></sec><sec id="s4-2"><title>Malignant fluid collection and primary cancer cell isolation</title><p>Malignant fluids were collected from five female BC patients by paracentesis (Patient # 1, 2, 4, and 5) or thoracentesis (Patient # 3) under informed consent and ethical compliance under Institutional Review Board (IRB) #07047 and #17334 at City of Hope. Selection criteria were determined from tumor type and treatment. Patient demographic data were not used for selection criteria. Upon collection of malignant fluid, cells were pelleted at 500 Ã <italic>g</italic> for 5 min, at room temperature. Red blood cells (RBCs) were then removed by lysis in Tris-ammonium chloride buffer (17 mM Tris, pH 7.4, 135 mM ammonium chloride) as previously described (<xref ref-type="bibr" rid="bib44">Nath et al., 2021</xref>) or by magnetic depletion using EasySep RBC Depletion Reagent (StemCell Technologies) diluting cell pellet in 2% FBS in phosphate-buffered saline (PBS) and incubated with 50 Âµl Depletion Reagent/ml for 5 min at room temperature, followed by two rounds of incubation on EasyEight magnet (StemCell Technologies) for 5 min. Primary human BC cells were then purified by magnetic depletion using the EasySep Dead Cell Removal (Annexin V) Kit (StemCell Technologies #17899) and EasySep CD45 Depletion Kit II (StemCell Technologies #17898) to remove dead cells and immune cells, respectively, as previously described (<xref ref-type="bibr" rid="bib44">Nath et al., 2021</xref>).</p></sec><sec id="s4-3"><title>Cell proliferation</title><p>For 2D experiments, cells were plated in 384-well plates and treated with increasing concentration of everolimus (0â100 nM) or ONC201/TIC10 (0â10 Î¼M) or combination ONC201/TIC10 (0â10 Î¼M) with everolimus (1 or 100 nM) for 4 days and viability was measured using CellTiter-Glo Luminescent Cell Viability Assay (Promega Corporation #G7573). Results were normalized to DMSO control treatment for each cell line. IC50 was determined using GraphPad Prism 9.3.1 software. Experiments were performed trice in quadruplicates and representative images are shown.</p><p>For 3D experiments, cells were plated in 96-well round-bottom ultra-low attachment spheroid microplate (Corning) at a density of 2000 cells per well (for CAMA-1 cells) or 5000 cells per well (for MCF7 and T47D cells). Spheroids were treated with drugs as indicated for up to 18 days with imaging and media change every 3â4 days. Imaging was performed using Cytation 5 imager (Biotek Instruments) gathering signal intensity from brightfield, YFP (for Venus fluorescence) and Texas Red (for mCherry fluorescence) channels. Raw data processing and image analysis were performed using Gen5 3.05 software as previously described (<xref ref-type="bibr" rid="bib18">Grolmusz et al., 2020</xref>). Briefly, stitching of 2 Ã 2 montage images and Z-projection using focus stacking was performed on raw images followed by spheroid area analysis. Whole spheroid area and fluorescence intensity measurements of each cell line are integrated into a fitted growth equation, and cell counts for each cell line were produced from fluorescence intensities relative to spheroid size. Experiments were performed trice in triplicates and representative image is shown. Bliss Interaction Index was calculated as previously described (<xref ref-type="bibr" rid="bib55">Soldi et al., 2013</xref>) with <italic>I</italic> &gt; 1 showing synergy and <italic>I</italic> = 1 showing additivity. For 2D assay Bliss Interaction Index was calculated from luminescence values and for 3D studies from fluorescence values.</p><p>For 3D experiments with primary cells, cells were plated in 96-well round-bottom ultra-low attachment spheroid microplate (Corning) at a density of 20,000 cells per well in Renaissance Essential Tumor Medium (Cellaria) supplemented with RETM Supplement (Cellaria), 10% FBS, 25 ng/ml cholera toxin (Sigma-Aldrich) and antibioticâantimycotic solution. After 2 days that spheroid structures were formed, spheroids were treated with drugs as indicated for 4 days. Brightfield imaging was performed using Cytation 5 imager (Biotek Instruments) before treatment and after 4 days of treatment. Viability was measured using CellTiter-Glo 3D Cell Viability Assay (Promega Corporation #G9682). Results were normalized to DMSO control. Experiments were performed in triplicates and representative image is shown.</p></sec><sec id="s4-4"><title>Western blot</title><p>For immunoblot analysis, cells were washed with PBS and lysed on ice in ice-cold Radioimmunoprecipitation assay buffer (RIPA) buffer (Thermo Scientific) supplemented with protease and phosphatase inhibitor cocktail (Thermo Scientific). The protein concentration in the lysates was determined using BCA (Pierce). Equal amounts of total protein were separated by sodium dodecyl sulfateâpolyacrylamide gel electrophoresis (SDSâPAGE) and 4â20% Tris-Glycine Gel (Bio-Rad) and were transferred to Polyvinylidene difluoride (PVDF) membranes using the iBlot Dry Blotting system (Invitrogen) according to the manufacturerâs instructions. Membranes were immunoblotted overnight with antibodies against BiP (C50B12) (#3177, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2119845">AB_2119845</ext-link>), pFoxO3a (Ser294) (#5538, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10696878">AB_10696878</ext-link>), FoxO3a (D19A7) (#12829, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2636990">AB_2636990</ext-link>), pERK1/2 Thr202/Tyr204 (197G2) (#4377, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331775">AB_331775</ext-link>), ERK1/2 (137F5) (#4695, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_390779">AB_390779</ext-link>), pAKT Ser473 (D9E) (#4060, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2315049">AB_2315049</ext-link>), AKT (C67E7) (#4691, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_915783">AB_915783</ext-link>), pS6Ser240/244 Ribosomal Protein (D68F8) (#5364, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10694233">AB_10694233</ext-link>), S6 Ribosomal Protein (54D2) (#2317, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2238583">AB_2238583</ext-link>), Î²-actin (8H10D10) (#12262, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2566811">AB_2566811</ext-link>), Î²-actin (13E5) (#5125, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1903890">AB_1903890</ext-link>) from Cell Signaling Technology, CREB-2/ATF-4 (B-3) (sc-390063, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2810998">AB_2810998</ext-link>), mtTFA (TFAM) (C-9) (sc-376672, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11150497">AB_11150497</ext-link>) from Santa Cruz Biotechnology, TUFM (#PA5-27511, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2544987">AB_2544987</ext-link>) and TRAIL (#MA1-41027, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1087999">AB_1087999</ext-link>) from Thermo Fisher Scientific and CHOP (Cat#15204-1-AP, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2292610">AB_2292610</ext-link>) from Proteintech. For the OXPHOS complexes detection, equal amounts of total protein were separated by SDSâPAGE and 16.5% Tris-Tricine Gel (Bio-Rad) and were transferred to PVDF membranes using the iBlot Dry Blotting system (Invitrogen) according to the manufacturerâs instructions. Membranes were immunoblotted overnight with total OXPHOS Human WB Antibody Cocktail (ab110411, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2756818">AB_2756818</ext-link>) from Abcam that contains 5 mAbs, against Complex I subunit NDUFB8, Complex II subunit 30 kDa, Complex III subunit Core 2, Complex IV subunit II, and ATP synthase subunit alpha. Quantitation of proteins was performed using ImageJ analysis. Experiments were performed thrice, and representative results are shown.</p></sec><sec id="s4-5"><title>Extracellular flux analysis</title><p>Mitochondrial respiration was determined using Agilent Seahorse XF Cell Mito Stress Test Kit (Agilent Technologies #103015-100) according to the manufacturerâs instructions. Cells were plated in XF96 Cell Culture Microplate (Agilent Technologies Inc) coated with Cell-Tak adhesive (Corning) at a density of 15,000 cells per well. Six hours later cells were treated with drugs as indicated for 18 hr. Before running the assay, cell culture media were replaced with Seahorse XF assay media supplemented with 10 mM XF Glucose, 1 mM XF Pyruvate and 2 mM XF L-Glutamine and the plate was incubated in a 37Â°C incubator without CO<sub>2</sub> for 1 hr. The OCR was measured by XFe96 extracellular flux analyzer (Agilent Technologies) with sequential injection of 1.5 Î¼M oligomycin A, 1 Î¼M Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), and 0.5 Î¼M rotenone/antimycin A. For normalization, imaging was performed using Cytation 5 imager (Biotek Instruments) gathering signal intensity from brightfield, YFP (for Venus fluorescence) and Texas Red (for mCherry fluorescence) channels. Raw data processing and image analysis were performed using Gen5 3.05 software. Briefly, Gen5 3.05 software detected and generated cell counts and fluorescence intensity measurements respective for each cell line within each well. Data analysis was performed using Seahorse Wave Desktop Software 2.6. OCR was normalized to cell number. Experiments were performed trice in triplicates and representative results are shown.</p></sec><sec id="s4-6"><title>Gene expression data and pre-processing</title><p>Microarray expression data from a neoadjuvant clinical trial of ER+ BC patients on everolimus were retrieved from NCBI GEO (accession number <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119262">GSE119262</ext-link>). The tumor samples were profiled using Illumina HumanRef-8 v2 Expression BeadChips and quantile normalized using BeadArray as described in <xref ref-type="bibr" rid="bib54">Sabine et al., 2010</xref>. The normalized gene expression matrix was aggregated by averaging expression levels of probes mapping to the same gene and by averaging the expression levels of technical replicates of the samples. RNA-seq data from MDA-MB-231 BC cell line treated with ONC201 were retrieved from NCBI GEO (accession number <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE212369">GSE212369</ext-link>). The samples were sequenced on the Illumina HiSeq 2500 platform, aligned to the h19 human genome reference using STAR, followed by gene level expression quantification using RSEM, as described in <xref ref-type="bibr" rid="bib16">Greer et al., 2018</xref>.</p></sec><sec id="s4-7"><title>Pathway activity scores and analysis</title><p>Gene signatures for 4705 curated (C2) gene signatures were retrieved from the molecular signatures database (mSigDB version 7.0) (<xref ref-type="bibr" rid="bib36">Liberzon et al., 2011</xref>). Single sample gene set enrichment scores were calculated from the normalized microarray (GSE119262) or RNA-seq (GSE212369) gene expression matrices using the R package GSVA (kcdf = âGaussianâ, method = âssgseaâ). To identify pathway signatures that change in response to everolimus treatment, we analyzed the ssGSEA scores of the 21 pairs of samples from patients with gene expression data collected before and after treatment. We split the samples into responsive and non-responsive groups and identified the pathways with significant difference in mean ssGSEA scores between pre- and post-treatment groups using a paired <italic>t</italic>-test. We investigated the changes in pathway signatures in response to ONC201/TIC10 treatment using gene expression data from MDA-MB-231 cells treated with ONC201/TIC10 data collected at 0, 3-, 6-, 12-, and 24-hr time points. We obtained ssGSEA scores for the pathway signatures at each time point and fit a generalized linear model (gaussian family) for each pathway signature against time. After obtaining nominal p-values of the fit for all signatures, we calculated false discovery rates to identify signatures that changed significantly over time.</p></sec><sec id="s4-8"><title>Statistical analysis</title><p>Doseâresponse curves were generated using GraphPad Prism 9.3.1 software and statistical comparisons were performed using one-way analysis of variance. All data are presented as average values of samples, error bars correspond to standard deviation. For all other experiments, graphs were generated using GraphPad Prism 9.3.1 and statistical comparisons of the results were performed using Studentâs two-tailed <italic>t</italic>-test (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Visualization, Methodology, Writing â original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Visualization, Methodology, Writing â original draft</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Visualization, Methodology, Writing â original draft</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con6"><p>Resources, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing â original draft</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Malignant fluids were collected from five female breast cancer patients by paracentesis (Patient # 1, 2, 4, and 5) or thoracentesis (Patient # 3) under informed consent and ethical compliance under Institutional Review Board (IRB) #07047 and #17334 at City of Hope.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-85898-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The data that support the findings of this study are included within the manuscript. Source data files have been provided for Figure 4. All gene expression datasets analyzed in this study are publicly available. ER+ breast cancer patients' data are available from NCBI GEO (accession number <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119262">GSE119262</ext-link>). RNA-seq data from MDA-MB-231 breast cancer cell lines are available from NCBI GEO (accession number <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE212369">GSE212369</ext-link>). Custom scripts used for the gene expression analyses are available on GitHub <ext-link ext-link-type="uri" xlink:href="https://github.com/U54Bioinformatics/ONC201_Manuscript_2022">https://github.com/U54Bioinformatics/ONC201_Manuscript_2022</ext-link> (copy archived at <xref ref-type="bibr" rid="bib45">Nath, 2022</xref>).</p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><name><surname>Sabine</surname><given-names>VS</given-names></name><name><surname>Sims</surname><given-names>AH</given-names></name><name><surname>Macaskill</surname><given-names>EJ</given-names></name><name><surname>Renshaw</surname><given-names>L</given-names></name><name><surname>Thomas</surname><given-names>JS</given-names></name><name><surname>Dixon</surname><given-names>JM</given-names></name><name><surname>Bartlett</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2010">2010</year><data-title>Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119262">GSE119262</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Greer</surname><given-names>YE</given-names></name><name><surname>Porat-Shliom</surname><given-names>N</given-names></name><name><surname>Nagashima</surname><given-names>K</given-names></name><name><surname>Stuelten</surname><given-names>C</given-names></name><name><surname>Crooks</surname><given-names>D</given-names></name><name><surname>Koparde</surname><given-names>VN</given-names></name><name><surname>Gilbert</surname><given-names>SF</given-names></name><name><surname>Islam</surname><given-names>C</given-names></name><name><surname>Ubaldini</surname><given-names>A</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>ONC201 kills breast cancer cells in vitro by targeting mitochondria</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE212369">GSE212369</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This study was supported by a US National Cancer Institute award number U01CA264620 and U54CA209978 awarded to AHB.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Krigsfeld</surname><given-names>G</given-names></name><name><surname>Mayes</surname><given-names>PA</given-names></name><name><surname>Patel</surname><given-names>L</given-names></name><name><surname>Dicker</surname><given-names>DT</given-names></name><name><surname>Patel</surname><given-names>AS</given-names></name><name><surname>Dolloff</surname><given-names>NG</given-names></name><name><surname>Messaris</surname><given-names>E</given-names></name><name><surname>Scata</surname><given-names>KA</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>JY</given-names></name><name><surname>Wu</surname><given-names>GS</given-names></name><name><surname>El-Deiry</surname><given-names>WS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects</article-title><source>Science Translational Medicine</source><volume>5</volume><elocation-id>171ra17</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3004828</pub-id><pub-id pub-id-type="pmid">23390247</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Madhoun</surname><given-names>A</given-names></name><name><surname>Haddad</surname><given-names>D</given-names></name><name><surname>Al Tarrah</surname><given-names>M</given-names></name><name><surname>Jacob</surname><given-names>S</given-names></name><name><surname>Al-Ali</surname><given-names>W</given-names></name><name><surname>Nizam</surname><given-names>R</given-names></name><name><surname>Miranda</surname><given-names>L</given-names></name><name><surname>Al-Rashed</surname><given-names>F</given-names></name><name><surname>Sindhu</surname><given-names>S</given-names></name><name><surname>Ahmad</surname><given-names>R</given-names></name><name><surname>Bitar</surname><given-names>MS</given-names></name><name><surname>Al-Mulla</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Microarray analysis reveals ONC201 mediated differential mechanisms of CHOP gene regulation in metastatic and nonmetastatic colorectal cancer cells</article-title><source>Scientific Reports</source><volume>11</volume><elocation-id>11893</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-91092-8</pub-id><pub-id pub-id-type="pmid">34088951</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Campone</surname><given-names>M</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Burris</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Sahmoud</surname><given-names>T</given-names></name><name><surname>Noguchi</surname><given-names>S</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><name><surname>Pritchard</surname><given-names>KI</given-names></name><name><surname>Lebrun</surname><given-names>F</given-names></name><name><surname>Beck</surname><given-names>JT</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Yardley</surname><given-names>D</given-names></name><name><surname>Deleu</surname><given-names>I</given-names></name><name><surname>Perez</surname><given-names>A</given-names></name><name><surname>Bachelot</surname><given-names>T</given-names></name><name><surname>Vittori</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Mukhopadhyay</surname><given-names>P</given-names></name><name><surname>Lebwohl</surname><given-names>D</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Everolimus in postmenopausal hormone-receptorâpositive advanced breast cancer</article-title><source>New England Journal of Medicine</source><volume>366</volume><fpage>520</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1109653</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bihani</surname><given-names>T</given-names></name><name><surname>Ezell</surname><given-names>SA</given-names></name><name><surname>Ladd</surname><given-names>B</given-names></name><name><surname>Grosskurth</surname><given-names>SE</given-names></name><name><surname>Mazzola</surname><given-names>AM</given-names></name><name><surname>Pietras</surname><given-names>M</given-names></name><name><surname>Reimer</surname><given-names>C</given-names></name><name><surname>Zinda</surname><given-names>M</given-names></name><name><surname>Fawell</surname><given-names>S</given-names></name><name><surname>DâCruz</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers</article-title><source>Oncotarget</source><volume>6</volume><fpage>2407</fpage><lpage>2420</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2964</pub-id><pub-id pub-id-type="pmid">25537515</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burdett</surname><given-names>E</given-names></name><name><surname>Kasper</surname><given-names>FK</given-names></name><name><surname>Mikos</surname><given-names>AG</given-names></name><name><surname>Ludwig</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Engineering tumors: a tissue engineering perspective in cancer biology</article-title><source>Tissue Engineering. Part B, Reviews</source><volume>16</volume><fpage>351</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1089/ten.TEB.2009.0676</pub-id><pub-id pub-id-type="pmid">20092396</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campone</surname><given-names>M</given-names></name><name><surname>Bachelot</surname><given-names>T</given-names></name><name><surname>Treilleux</surname><given-names>I</given-names></name><name><surname>Pistilli</surname><given-names>B</given-names></name><name><surname>Salleron</surname><given-names>J</given-names></name><name><surname>Seegers</surname><given-names>V</given-names></name><name><surname>Arnedos</surname><given-names>M</given-names></name><name><surname>Loussouarn</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Vanlemmens</surname><given-names>L</given-names></name><name><surname>Jimenez</surname><given-names>M</given-names></name><name><surname>Rios</surname><given-names>M</given-names></name><name><surname>DiÃ©ras</surname><given-names>V</given-names></name><name><surname>Leroux</surname><given-names>A</given-names></name><name><surname>Paintaud</surname><given-names>G</given-names></name><name><surname>Rezai</surname><given-names>K</given-names></name><name><surname>AndrÃ©</surname><given-names>F</given-names></name><name><surname>Lion</surname><given-names>M</given-names></name><name><surname>Merlin</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)</article-title><source>European Journal of Cancer</source><volume>158</volume><fpage>169</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2021.09.017</pub-id><pub-id pub-id-type="pmid">34678678</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carew</surname><given-names>JS</given-names></name><name><surname>Kelly</surname><given-names>KR</given-names></name><name><surname>Nawrocki</surname><given-names>ST</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mechanisms of mTOR inhibitor resistance in cancer therapy</article-title><source>Targeted Oncology</source><volume>6</volume><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1007/s11523-011-0167-8</pub-id><pub-id pub-id-type="pmid">21547705</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Hao</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Zu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer</article-title><source>Molecular Cancer Research</source><volume>11</volume><fpage>1269</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-13-0212</pub-id><pub-id pub-id-type="pmid">23814023</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cormio</surname><given-names>A</given-names></name><name><surname>Sanguedolce</surname><given-names>F</given-names></name><name><surname>Pesce</surname><given-names>V</given-names></name><name><surname>Musicco</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mitochondrial caseinolytic protease p: A possible novel prognostic marker and therapeutic target in cancer</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>6228</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22126228</pub-id><pub-id pub-id-type="pmid">34207660</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhen</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Mu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway</article-title><source>Molecular Medicine Reports</source><volume>17</volume><fpage>7163</fpage><lpage>7169</lpage><pub-id pub-id-type="doi">10.3892/mmr.2018.8769</pub-id><pub-id pub-id-type="pmid">29568883</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dwucet</surname><given-names>A</given-names></name><name><surname>Pruss</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>Q</given-names></name><name><surname>Tanriover</surname><given-names>M</given-names></name><name><surname>Prabhu</surname><given-names>VV</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Peraud</surname><given-names>A</given-names></name><name><surname>Westhoff</surname><given-names>M-A</given-names></name><name><surname>Siegelin</surname><given-names>MD</given-names></name><name><surname>Wirtz</surname><given-names>CR</given-names></name><name><surname>Karpel-Massler</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells <italic>in Vitro</italic> Independent of C-Myc Expression</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>9</volume><elocation-id>734699</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.734699</pub-id><pub-id pub-id-type="pmid">34900991</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>KW</given-names></name><name><surname>Yuca</surname><given-names>E</given-names></name><name><surname>Scott</surname><given-names>SS</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Paez Arango</surname><given-names>N</given-names></name><name><surname>Cruz Pico</surname><given-names>CX</given-names></name><name><surname>Saridogan</surname><given-names>T</given-names></name><name><surname>Shariati</surname><given-names>M</given-names></name><name><surname>Class</surname><given-names>CA</given-names></name><name><surname>Bristow</surname><given-names>CA</given-names></name><name><surname>Vellano</surname><given-names>CP</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Gonzalez-Angulo</surname><given-names>AM</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Tapia</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Akcakanat</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>B</given-names></name><name><surname>Tripathy</surname><given-names>D</given-names></name><name><surname>Yap</surname><given-names>TA</given-names></name><name><surname>Francesco</surname><given-names>MED</given-names></name><name><surname>Draetta</surname><given-names>GF</given-names></name><name><surname>Jones</surname><given-names>P</given-names></name><name><surname>Heffernan</surname><given-names>TP</given-names></name><name><surname>Marszalek</surname><given-names>JR</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple-negative breast cancer</article-title><source>Cancer Research</source><volume>81</volume><fpage>5572</fpage><lpage>5581</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-3242</pub-id><pub-id pub-id-type="pmid">34518211</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faivre</surname><given-names>S</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Raymond</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Current development of mTOR inhibitors as anticancer agents</article-title><source>Nature Reviews. Drug Discovery</source><volume>5</volume><fpage>671</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1038/nrd2062</pub-id><pub-id pub-id-type="pmid">16883305</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Pierce</surname><given-names>SR</given-names></name><name><surname>West</surname><given-names>L</given-names></name><name><surname>Staley</surname><given-names>A</given-names></name><name><surname>Tucker</surname><given-names>K</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Kong</surname><given-names>W</given-names></name><name><surname>Prabhu</surname><given-names>V</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Bae-Jump</surname><given-names>VL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Anti-tumor and anti-invasive effects of ONC201 on ovarian cancer cells and a transgenic mouse model of serous ovarian cancer</article-title><source>Frontiers in Oncology</source><volume>12</volume><elocation-id>789450</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2022.789450</pub-id><pub-id pub-id-type="pmid">35372029</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graves</surname><given-names>PR</given-names></name><name><surname>Aponte-Collazo</surname><given-names>LJ</given-names></name><name><surname>Fennell</surname><given-names>EMJ</given-names></name><name><surname>Graves</surname><given-names>AC</given-names></name><name><surname>Hale</surname><given-names>AE</given-names></name><name><surname>Dicheva</surname><given-names>N</given-names></name><name><surname>Herring</surname><given-names>LE</given-names></name><name><surname>Gilbert</surname><given-names>TSK</given-names></name><name><surname>East</surname><given-names>MP</given-names></name><name><surname>McDonald</surname><given-names>IM</given-names></name><name><surname>Lockett</surname><given-names>MR</given-names></name><name><surname>Ashamalla</surname><given-names>H</given-names></name><name><surname>Moorman</surname><given-names>NJ</given-names></name><name><surname>Karanewsky</surname><given-names>DS</given-names></name><name><surname>Iwanowicz</surname><given-names>EJ</given-names></name><name><surname>Holmuhamedov</surname><given-names>E</given-names></name><name><surname>Graves</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mitochondrial protease ClpP is a target for the anticancer compounds ONC201 and related analogues</article-title><source>ACS Chemical Biology</source><volume>14</volume><fpage>1020</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1021/acschembio.9b00222</pub-id><pub-id pub-id-type="pmid">31021596</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greer</surname><given-names>YE</given-names></name><name><surname>Porat-Shliom</surname><given-names>N</given-names></name><name><surname>Nagashima</surname><given-names>K</given-names></name><name><surname>Stuelten</surname><given-names>C</given-names></name><name><surname>Crooks</surname><given-names>D</given-names></name><name><surname>Koparde</surname><given-names>VN</given-names></name><name><surname>Gilbert</surname><given-names>SF</given-names></name><name><surname>Islam</surname><given-names>C</given-names></name><name><surname>Ubaldini</surname><given-names>A</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Soheilian</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hafner</surname><given-names>M</given-names></name><name><surname>Shetty</surname><given-names>J</given-names></name><name><surname>Tran</surname><given-names>B</given-names></name><name><surname>Jailwala</surname><given-names>P</given-names></name><name><surname>Cam</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>M</given-names></name><name><surname>Voeller</surname><given-names>D</given-names></name><name><surname>Reinhold</surname><given-names>WC</given-names></name><name><surname>Rajapakse</surname><given-names>V</given-names></name><name><surname>Pommier</surname><given-names>Y</given-names></name><name><surname>Weigert</surname><given-names>R</given-names></name><name><surname>Linehan</surname><given-names>WM</given-names></name><name><surname>Lipkowitz</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ONC201 kills breast cancer cells <italic>in vitro</italic> by targeting mitochondria</article-title><source>Oncotarget</source><volume>9</volume><fpage>18454</fpage><lpage>18479</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.24862</pub-id><pub-id pub-id-type="pmid">29719618</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greer</surname><given-names>YE</given-names></name><name><surname>Hernandez</surname><given-names>L</given-names></name><name><surname>Fennell</surname><given-names>EMJ</given-names></name><name><surname>Kundu</surname><given-names>M</given-names></name><name><surname>Voeller</surname><given-names>D</given-names></name><name><surname>Chari</surname><given-names>R</given-names></name><name><surname>Gilbert</surname><given-names>SF</given-names></name><name><surname>Gilbert</surname><given-names>TSK</given-names></name><name><surname>Ratnayake</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>B</given-names></name><name><surname>Hafner</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Meerzaman</surname><given-names>D</given-names></name><name><surname>Iwanowicz</surname><given-names>E</given-names></name><name><surname>Annunziata</surname><given-names>CM</given-names></name><name><surname>Graves</surname><given-names>LM</given-names></name><name><surname>Lipkowitz</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis</article-title><source>Cancer Research Communications</source><volume>2</volume><fpage>1144</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1158/2767-9764.CRC-22-0142</pub-id><pub-id pub-id-type="pmid">36388465</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grolmusz</surname><given-names>VK</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Emond</surname><given-names>R</given-names></name><name><surname>Cosgrove</surname><given-names>PA</given-names></name><name><surname>Pflieger</surname><given-names>L</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Moos</surname><given-names>PJ</given-names></name><name><surname>Bild</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model</article-title><source>Cancer Cell International</source><volume>20</volume><elocation-id>253</elocation-id><pub-id pub-id-type="doi">10.1186/s12935-020-01337-1</pub-id><pub-id pub-id-type="pmid">32565737</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Multicellular spheroids as an in vitro tumor model</article-title><source>Cancer Letters</source><volume>131</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/s0304-3835(98)00198-0</pub-id><pub-id pub-id-type="pmid">9839617</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hare</surname><given-names>SH</given-names></name><name><surname>Harvey</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>mTOR function and therapeutic targeting in breast cancer</article-title><source>American Journal of Cancer Research</source><volume>7</volume><fpage>383</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">28400999</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holder</surname><given-names>AM</given-names></name><name><surname>Akcakanat</surname><given-names>A</given-names></name><name><surname>Adkins</surname><given-names>F</given-names></name><name><surname>Evans</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>C</given-names></name><name><surname>Milton</surname><given-names>DR</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Do</surname><given-names>K-A</given-names></name><name><surname>Janku</surname><given-names>F</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Epithelial to mesenchymal transition is associated with rapamycin resistance</article-title><source>Oncotarget</source><volume>6</volume><fpage>19500</fpage><lpage>19513</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3669</pub-id><pub-id pub-id-type="pmid">25944619</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The C/EBP Homologous Protein (CHOP) Transcription Factor Functions in Endoplasmic Reticulum Stress-Induced Apoptosis and Microbial Infection</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>3083</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.03083</pub-id><pub-id pub-id-type="pmid">30662442</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imamura</surname><given-names>Y</given-names></name><name><surname>Mukohara</surname><given-names>T</given-names></name><name><surname>Shimono</surname><given-names>Y</given-names></name><name><surname>Funakoshi</surname><given-names>Y</given-names></name><name><surname>Chayahara</surname><given-names>N</given-names></name><name><surname>Toyoda</surname><given-names>M</given-names></name><name><surname>Kiyota</surname><given-names>N</given-names></name><name><surname>Takao</surname><given-names>S</given-names></name><name><surname>Kono</surname><given-names>S</given-names></name><name><surname>Nakatsura</surname><given-names>T</given-names></name><name><surname>Minami</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer</article-title><source>Oncology Reports</source><volume>33</volume><fpage>1837</fpage><lpage>1843</lpage><pub-id pub-id-type="doi">10.3892/or.2015.3767</pub-id><pub-id pub-id-type="pmid">25634491</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>CT</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Bianchetti</surname><given-names>E</given-names></name><name><surname>Shu</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>TTT</given-names></name><name><surname>Kleiner</surname><given-names>G</given-names></name><name><surname>Sanchez-Quintero</surname><given-names>MJ</given-names></name><name><surname>Quinzii</surname><given-names>CM</given-names></name><name><surname>Westhoff</surname><given-names>M-A</given-names></name><name><surname>Karpel-Massler</surname><given-names>G</given-names></name><name><surname>Prabhu</surname><given-names>VV</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Siegelin</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Metabolic reprogramming by dual AKT/ERK inhibition through imipridones elicits unique vulnerabilities in glioblastoma</article-title><source>Clinical Cancer Research</source><volume>24</volume><fpage>5392</fpage><lpage>5406</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-1040</pub-id><pub-id pub-id-type="pmid">30037819</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishizawa</surname><given-names>J</given-names></name><name><surname>Kojima</surname><given-names>K</given-names></name><name><surname>Chachad</surname><given-names>D</given-names></name><name><surname>Ruvolo</surname><given-names>P</given-names></name><name><surname>Ruvolo</surname><given-names>V</given-names></name><name><surname>Jacamo</surname><given-names>RO</given-names></name><name><surname>Borthakur</surname><given-names>G</given-names></name><name><surname>Mu</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Tabe</surname><given-names>Y</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Orlowski</surname><given-names>R</given-names></name><name><surname>Sarbassov</surname><given-names>DD</given-names></name><name><surname>Lorenzi</surname><given-names>PL</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Neelapu</surname><given-names>SS</given-names></name><name><surname>McDonnell</surname><given-names>T</given-names></name><name><surname>Miranda</surname><given-names>RN</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Konopleva</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>RE</given-names></name><name><surname>Andreeff</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies</article-title><source>Science Signaling</source><volume>9</volume><elocation-id>ra17</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aac4380</pub-id><pub-id pub-id-type="pmid">26884599</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishizawa</surname><given-names>J</given-names></name><name><surname>Zarabi</surname><given-names>SF</given-names></name><name><surname>Davis</surname><given-names>RE</given-names></name><name><surname>Halgas</surname><given-names>O</given-names></name><name><surname>Nii</surname><given-names>T</given-names></name><name><surname>Jitkova</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>St-Germain</surname><given-names>J</given-names></name><name><surname>Heese</surname><given-names>LE</given-names></name><name><surname>Egan</surname><given-names>G</given-names></name><name><surname>Ruvolo</surname><given-names>VR</given-names></name><name><surname>Barghout</surname><given-names>SH</given-names></name><name><surname>Nishida</surname><given-names>Y</given-names></name><name><surname>Hurren</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Gronda</surname><given-names>M</given-names></name><name><surname>Link</surname><given-names>T</given-names></name><name><surname>Wong</surname><given-names>K</given-names></name><name><surname>Mabanglo</surname><given-names>M</given-names></name><name><surname>Kojima</surname><given-names>K</given-names></name><name><surname>Borthakur</surname><given-names>G</given-names></name><name><surname>MacLean</surname><given-names>N</given-names></name><name><surname>Ma</surname><given-names>MCJ</given-names></name><name><surname>Leber</surname><given-names>AB</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>Houry</surname><given-names>W</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Stogniew</surname><given-names>M</given-names></name><name><surname>Raught</surname><given-names>B</given-names></name><name><surname>Pai</surname><given-names>EF</given-names></name><name><surname>Schimmer</surname><given-names>AD</given-names></name><name><surname>Andreeff</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality</article-title><source>Cancer Cell</source><volume>35</volume><fpage>721</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.03.014</pub-id><pub-id pub-id-type="pmid">31056398</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacques</surname><given-names>S</given-names></name><name><surname>van der Sloot</surname><given-names>AM</given-names></name><name><surname>C Huard</surname><given-names>C</given-names></name><name><surname>Coulombe-Huntington</surname><given-names>J</given-names></name><name><surname>Tsao</surname><given-names>S</given-names></name><name><surname>Tollis</surname><given-names>S</given-names></name><name><surname>Bertomeu</surname><given-names>T</given-names></name><name><surname>Culp</surname><given-names>EJ</given-names></name><name><surname>Pallant</surname><given-names>D</given-names></name><name><surname>Cook</surname><given-names>MA</given-names></name><name><surname>Bonneil</surname><given-names>E</given-names></name><name><surname>Thibault</surname><given-names>P</given-names></name><name><surname>Wright</surname><given-names>GD</given-names></name><name><surname>Tyers</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Imipridone anticancer compounds ectopically activate the ClpP protease and represent a new scaffold for antibiotic development</article-title><source>Genetics</source><volume>214</volume><fpage>1103</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1534/genetics.119.302851</pub-id><pub-id pub-id-type="pmid">32094149</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>ZZ</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Fang</surname><given-names>DL</given-names></name><name><surname>Jin</surname><given-names>YJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity</article-title><source>Biochemical and Biophysical Research Communications</source><volume>478</volume><fpage>1515</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2016.08.126</pub-id><pub-id pub-id-type="pmid">27565731</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>SRD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer: Cotargeting signaling pathways</article-title><source>Journal of the National Cancer Institute</source><volume>107</volume><elocation-id>djv212</elocation-id><pub-id pub-id-type="doi">10.1093/jnci/djv212</pub-id><pub-id pub-id-type="pmid">26251289</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Hanamura</surname><given-names>T</given-names></name><name><surname>Tsuboi</surname><given-names>K</given-names></name><name><surname>Kaneko</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Niwa</surname><given-names>T</given-names></name><name><surname>Narui</surname><given-names>K</given-names></name><name><surname>Endo</surname><given-names>I</given-names></name><name><surname>Hayashi</surname><given-names>SI</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer</article-title><source>Oncotarget</source><volume>9</volume><fpage>21468</fpage><lpage>21477</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.25133</pub-id><pub-id pub-id-type="pmid">29765553</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kline</surname><given-names>CLB</given-names></name><name><surname>Van den Heuvel</surname><given-names>APJ</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Prabhu</surname><given-names>VV</given-names></name><name><surname>Dicker</surname><given-names>DT</given-names></name><name><surname>El-Deiry</surname><given-names>WS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2Î± kinases</article-title><source>Science Signaling</source><volume>9</volume><elocation-id>ra18</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aac4374</pub-id><pub-id pub-id-type="pmid">26884600</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kline</surname><given-names>CLB</given-names></name><name><surname>Ralff</surname><given-names>MD</given-names></name><name><surname>Lulla</surname><given-names>AR</given-names></name><name><surname>Wagner</surname><given-names>JM</given-names></name><name><surname>Abbosh</surname><given-names>PH</given-names></name><name><surname>Dicker</surname><given-names>DT</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>El-Deiry</surname><given-names>WS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Role of dopamine receptors in the anticancer activity of ONC201</article-title><source>Neoplasia</source><volume>20</volume><fpage>80</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2017.10.002</pub-id><pub-id pub-id-type="pmid">29216597</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langhans</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Three-dimensional <italic>in vitro</italic> cell culture models in drug discovery and drug repositioning</article-title><source>Frontiers in Pharmacology</source><volume>9</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2018.00006</pub-id><pub-id pub-id-type="pmid">29410625</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Forrester</surname><given-names>E</given-names></name><name><surname>Chytil</surname><given-names>A</given-names></name><name><surname>Corsino</surname><given-names>P</given-names></name><name><surname>Green</surname><given-names>G</given-names></name><name><surname>Davis</surname><given-names>B</given-names></name><name><surname>Rowe</surname><given-names>T</given-names></name><name><surname>Law</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes</article-title><source>Cancer Research</source><volume>66</volume><fpage>1070</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1672</pub-id><pub-id pub-id-type="pmid">16424043</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lev</surname><given-names>A</given-names></name><name><surname>Lulla</surname><given-names>AR</given-names></name><name><surname>Ross</surname><given-names>BC</given-names></name><name><surname>Ralff</surname><given-names>MD</given-names></name><name><surname>Makhov</surname><given-names>PB</given-names></name><name><surname>Dicker</surname><given-names>DT</given-names></name><name><surname>El-Deiry</surname><given-names>WS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer</article-title><source>Molecular Cancer Research</source><volume>16</volume><fpage>754</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-17-0614</pub-id><pub-id pub-id-type="pmid">29588330</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Pinchback</surname><given-names>R</given-names></name><name><surname>ThorvaldsdÃ³ttir</surname><given-names>H</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Molecular signatures database (MSigDB) 3.0</article-title><source>Bioinformatics</source><volume>27</volume><fpage>1739</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr260</pub-id><pub-id pub-id-type="pmid">21546393</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovitt</surname><given-names>CJ</given-names></name><name><surname>Shelper</surname><given-names>TB</given-names></name><name><surname>Avery</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Evaluation of chemotherapeutics in a three-dimensional breast cancer model</article-title><source>Journal of Cancer Research and Clinical Oncology</source><volume>141</volume><fpage>951</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1007/s00432-015-1950-1</pub-id><pub-id pub-id-type="pmid">25773123</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lui</surname><given-names>A</given-names></name><name><surname>New</surname><given-names>J</given-names></name><name><surname>Ogony</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Lewis-Wambi</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells</article-title><source>BMC Cancer</source><volume>16</volume><elocation-id>487</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-016-2490-z</pub-id><pub-id pub-id-type="pmid">27421652</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>B</given-names></name><name><surname>Tao</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Ren</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>ClpP regulates breast cancer cell proliferation, invasion and apoptosis by modulating the Src/PI3K/Akt signaling pathway</article-title><source>PeerJ</source><volume>8</volume><elocation-id>e8754</elocation-id><pub-id pub-id-type="doi">10.7717/peerj.8754</pub-id><pub-id pub-id-type="pmid">32195060</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDermott</surname><given-names>M</given-names></name><name><surname>Eustace</surname><given-names>AJ</given-names></name><name><surname>Busschots</surname><given-names>S</given-names></name><name><surname>Breen</surname><given-names>L</given-names></name><name><surname>Crown</surname><given-names>J</given-names></name><name><surname>Clynes</surname><given-names>M</given-names></name><name><surname>OâDonovan</surname><given-names>N</given-names></name><name><surname>Stordal</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies</article-title><source>Frontiers in Oncology</source><volume>4</volume><elocation-id>40</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2014.00040</pub-id><pub-id pub-id-type="pmid">24639951</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendoza</surname><given-names>MC</given-names></name><name><surname>Er</surname><given-names>EE</given-names></name><name><surname>Blenis</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation</article-title><source>Trends in Biochemical Sciences</source><volume>36</volume><fpage>320</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2011.03.006</pub-id><pub-id pub-id-type="pmid">21531565</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>JR</given-names></name><name><surname>Hippo</surname><given-names>Y</given-names></name><name><surname>Robert</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>SMH</given-names></name><name><surname>Malina</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>CJ</given-names></name><name><surname>Trojahn</surname><given-names>U</given-names></name><name><surname>Wendel</surname><given-names>HG</given-names></name><name><surname>Charest</surname><given-names>A</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Kogan</surname><given-names>SC</given-names></name><name><surname>Nadon</surname><given-names>R</given-names></name><name><surname>Housman</surname><given-names>DE</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Pelletier</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>mTORC1 promotes survival through translational control of Mcl-1</article-title><source>PNAS</source><volume>105</volume><fpage>10853</fpage><lpage>10858</lpage><pub-id pub-id-type="doi">10.1073/pnas.0804821105</pub-id><pub-id pub-id-type="pmid">18664580</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mita</surname><given-names>MM</given-names></name><name><surname>Mita</surname><given-names>A</given-names></name><name><surname>Rowinsky</surname><given-names>EK</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Mammalian target of rapamycin: a new molecular target for breast cancer</article-title><source>Clinical Breast Cancer</source><volume>4</volume><fpage>126</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.3816/cbc.2003.n.018</pub-id><pub-id pub-id-type="pmid">12864941</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Cosgrove</surname><given-names>PA</given-names></name><name><surname>Mirsafian</surname><given-names>H</given-names></name><name><surname>Christie</surname><given-names>EL</given-names></name><name><surname>Pflieger</surname><given-names>L</given-names></name><name><surname>Copeland</surname><given-names>B</given-names></name><name><surname>Majumdar</surname><given-names>S</given-names></name><name><surname>Cristea</surname><given-names>MC</given-names></name><name><surname>Han</surname><given-names>ES</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>EW</given-names></name><name><surname>Fereday</surname><given-names>S</given-names></name><name><surname>Traficante</surname><given-names>N</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name><name><surname>Werner</surname><given-names>T</given-names></name><name><surname>Cohen</surname><given-names>AL</given-names></name><name><surname>Moos</surname><given-names>P</given-names></name><name><surname>Chang</surname><given-names>JT</given-names></name><name><surname>Bowtell</surname><given-names>DDL</given-names></name><name><surname>Bild</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>3039</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-23171-3</pub-id><pub-id pub-id-type="pmid">34031395</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Onc201_Manuscript_2022</data-title><version designator="swh:1:rev:ce2d657d90c7d113cd855aacd057c4c81924fc46">swh:1:rev:ce2d657d90c7d113cd855aacd057c4c81924fc46</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:9db91e24726a166632c9381019576b88ec566c9b;origin=https://github.com/U54Bioinformatics/ONC201_Manuscript_2022;visit=swh:1:snp:43dc9a80048c2fd12af8fd4114f26a5ae9d0b879;anchor=swh:1:rev:ce2d657d90c7d113cd855aacd057c4c81924fc46">https://archive.softwareheritage.org/swh:1:dir:9db91e24726a166632c9381019576b88ec566c9b;origin=https://github.com/U54Bioinformatics/ONC201_Manuscript_2022;visit=swh:1:snp:43dc9a80048c2fd12af8fd4114f26a5ae9d0b879;anchor=swh:1:rev:ce2d657d90c7d113cd855aacd057c4c81924fc46</ext-link></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neklesa</surname><given-names>TK</given-names></name><name><surname>Davis</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Superoxide anions regulate TORC1 and its ability to bind Fpr1:rapamycin complex</article-title><source>PNAS</source><volume>105</volume><fpage>15166</fpage><lpage>15171</lpage><pub-id pub-id-type="doi">10.1073/pnas.0807712105</pub-id><pub-id pub-id-type="pmid">18812505</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortolani</surname><given-names>S</given-names></name><name><surname>Ciccarese</surname><given-names>C</given-names></name><name><surname>Cingarlini</surname><given-names>S</given-names></name><name><surname>Tortora</surname><given-names>G</given-names></name><name><surname>Massari</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives</article-title><source>Future Oncology</source><volume>11</volume><fpage>1809</fpage><lpage>1828</lpage><pub-id pub-id-type="doi">10.2217/fon.15.81</pub-id><pub-id pub-id-type="pmid">26075448</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osborne</surname><given-names>CK</given-names></name><name><surname>Schiff</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mechanisms of endocrine resistance in breast cancer</article-title><source>Annual Review of Medicine</source><volume>62</volume><fpage>233</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-070909-182917</pub-id><pub-id pub-id-type="pmid">20887199</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prabhu</surname><given-names>VV</given-names></name><name><surname>Morrow</surname><given-names>S</given-names></name><name><surname>Rahman Kawakibi</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Ralff</surname><given-names>M</given-names></name><name><surname>Ray</surname><given-names>J</given-names></name><name><surname>Jhaveri</surname><given-names>A</given-names></name><name><surname>Ferrarini</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Parker</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Borsuk</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>W-I</given-names></name><name><surname>Honeyman</surname><given-names>JN</given-names></name><name><surname>Tavora</surname><given-names>F</given-names></name><name><surname>Carneiro</surname><given-names>B</given-names></name><name><surname>Raufi</surname><given-names>A</given-names></name><name><surname>Huntington</surname><given-names>K</given-names></name><name><surname>Carlsen</surname><given-names>L</given-names></name><name><surname>Louie</surname><given-names>A</given-names></name><name><surname>Safran</surname><given-names>H</given-names></name><name><surname>Seyhan</surname><given-names>AA</given-names></name><name><surname>Tarapore</surname><given-names>RS</given-names></name><name><surname>Schalop</surname><given-names>L</given-names></name><name><surname>Stogniew</surname><given-names>M</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Oster</surname><given-names>W</given-names></name><name><surname>El-Deiry</surname><given-names>WS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>ONC201 and imipridones: Anti-cancer compounds with clinical efficacy</article-title><source>Neoplasia</source><volume>22</volume><fpage>725</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2020.09.005</pub-id><pub-id pub-id-type="pmid">33142238</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pruss</surname><given-names>M</given-names></name><name><surname>Dwucet</surname><given-names>A</given-names></name><name><surname>Tanriover</surname><given-names>M</given-names></name><name><surname>Hlavac</surname><given-names>M</given-names></name><name><surname>Kast</surname><given-names>RE</given-names></name><name><surname>Debatin</surname><given-names>K-M</given-names></name><name><surname>Wirtz</surname><given-names>CR</given-names></name><name><surname>Halatsch</surname><given-names>M-E</given-names></name><name><surname>Siegelin</surname><given-names>MD</given-names></name><name><surname>Westhoff</surname><given-names>M-A</given-names></name><name><surname>Karpel-Massler</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma</article-title><source>British Journal of Cancer</source><volume>122</volume><fpage>1146</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1038/s41416-020-0759-0</pub-id><pub-id pub-id-type="pmid">32115576</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pusapati</surname><given-names>RV</given-names></name><name><surname>Daemen</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Sandoval</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Haley</surname><given-names>B</given-names></name><name><surname>Baudy</surname><given-names>AR</given-names></name><name><surname>Hatzivassiliou</surname><given-names>G</given-names></name><name><surname>Evangelista</surname><given-names>M</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>mTORC1-dependent metabolic reprogramming underlies escape from glycolysis addiction in cancer cells</article-title><source>Cancer Cell</source><volume>29</volume><fpage>548</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.02.018</pub-id><pub-id pub-id-type="pmid">27052953</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ralff</surname><given-names>MD</given-names></name><name><surname>Kline</surname><given-names>CLB</given-names></name><name><surname>KÃ¼Ã§Ã¼kkase</surname><given-names>OC</given-names></name><name><surname>Wagner</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>B</given-names></name><name><surname>Dicker</surname><given-names>DT</given-names></name><name><surname>Prabhu</surname><given-names>VV</given-names></name><name><surname>Oster</surname><given-names>W</given-names></name><name><surname>El-Deiry</surname><given-names>WS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms</article-title><source>Molecular Cancer Therapeutics</source><volume>16</volume><fpage>1290</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-0121</pub-id><pub-id pub-id-type="pmid">28424227</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rumman</surname><given-names>M</given-names></name><name><surname>Buck</surname><given-names>S</given-names></name><name><surname>Polin</surname><given-names>L</given-names></name><name><surname>Dzinic</surname><given-names>S</given-names></name><name><surname>Boerner</surname><given-names>J</given-names></name><name><surname>Winer</surname><given-names>IS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity</article-title><source>Cancer Medicine</source><volume>10</volume><fpage>3373</fpage><lpage>3387</lpage><pub-id pub-id-type="doi">10.1002/cam4.3858</pub-id><pub-id pub-id-type="pmid">33932119</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabine</surname><given-names>VS</given-names></name><name><surname>Sims</surname><given-names>AH</given-names></name><name><surname>Macaskill</surname><given-names>EJ</given-names></name><name><surname>Renshaw</surname><given-names>L</given-names></name><name><surname>Thomas</surname><given-names>JS</given-names></name><name><surname>Dixon</surname><given-names>JM</given-names></name><name><surname>Bartlett</surname><given-names>JMS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer</article-title><source>Breast Cancer Research and Treatment</source><volume>122</volume><fpage>419</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1007/s10549-010-0928-6</pub-id><pub-id pub-id-type="pmid">20480226</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soldi</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>AL</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Moos</surname><given-names>PJ</given-names></name><name><surname>Bild</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A genomic approach to predict synergistic combinations for breast cancer treatment</article-title><source>The Pharmacogenomics Journal</source><volume>13</volume><fpage>94</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1038/tpj.2011.48</pub-id><pub-id pub-id-type="pmid">22083351</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staley</surname><given-names>A</given-names></name><name><surname>Tucker</surname><given-names>K</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Suo</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Prabhu</surname><given-names>VV</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Bae-Jump</surname><given-names>VL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer</article-title><source>American Journal of Cancer Research</source><volume>11</volume><fpage>5374</fpage><lpage>5387</lpage><pub-id pub-id-type="pmid">34873466</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szegezdi</surname><given-names>E</given-names></name><name><surname>Logue</surname><given-names>SE</given-names></name><name><surname>Gorman</surname><given-names>AM</given-names></name><name><surname>Samali</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mediators of endoplasmic reticulum stress-induced apoptosis</article-title><source>EMBO Reports</source><volume>7</volume><fpage>880</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1038/sj.embor.7400779</pub-id><pub-id pub-id-type="pmid">16953201</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taglieri</surname><given-names>L</given-names></name><name><surname>De Iuliis</surname><given-names>F</given-names></name><name><surname>Giuffrida</surname><given-names>A</given-names></name><name><surname>Giantulli</surname><given-names>S</given-names></name><name><surname>Silvestri</surname><given-names>I</given-names></name><name><surname>Scarpa</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells</article-title><source>Oncology Letters</source><volume>14</volume><fpage>3832</fpage><lpage>3838</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.6597</pub-id><pub-id pub-id-type="pmid">28927154</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Dougan</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Direct Molecular Target for Imipridone ONC201 Is Finally Established</article-title><source>Cancer Cell</source><volume>35</volume><fpage>707</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.04.010</pub-id><pub-id pub-id-type="pmid">31085171</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wangpaichitr</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>You</surname><given-names>M</given-names></name><name><surname>Kuo</surname><given-names>MT</given-names></name><name><surname>Feun</surname><given-names>L</given-names></name><name><surname>Lampidis</surname><given-names>T</given-names></name><name><surname>Savaraj</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins</article-title><source>European Journal of Pharmacology</source><volume>591</volume><fpage>124</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2008.06.028</pub-id><pub-id pub-id-type="pmid">18585380</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>K</given-names></name><name><surname>Bartsch</surname><given-names>U</given-names></name><name><surname>Stocking</surname><given-names>C</given-names></name><name><surname>Fehse</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A multicolor panel of novel lentiviral âgene ontologyâ (LeGO) vectors for functional gene analysis</article-title><source>Molecular Therapy</source><volume>16</volume><fpage>698</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1038/mt.2008.6</pub-id><pub-id pub-id-type="pmid">18362927</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wortel</surname><given-names>IMN</given-names></name><name><surname>van der Meer</surname><given-names>LT</given-names></name><name><surname>Kilberg</surname><given-names>MS</given-names></name><name><surname>van Leeuwen</surname><given-names>FN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Surviving Stress: Modulation of ATF4-Mediated Stress Responses in Normal and Malignant Cells</article-title><source>Trends in Endocrinology and Metabolism</source><volume>28</volume><fpage>794</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2017.07.003</pub-id><pub-id pub-id-type="pmid">28797581</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Kho</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gajan</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells</article-title><source>Oncotarget</source><volume>8</volume><fpage>21626</fpage><lpage>21638</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.15451</pub-id><pub-id pub-id-type="pmid">28423492</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85898.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yongliang</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/023hj5876</institution-id><institution>Dalian University of Technology</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.12.27.522019" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.12.27.522019"/></front-stub><body><p>The study by Bild et al. reported a valuable finding on the combination use of ONC201/TIC10 towards ER+ breast cancer. The data of the manuscript is rather solid. The paper may produce translational impact and scientists working in the field of breast cancer may benefit most from the work.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85898.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Yang</surname><given-names>Yongliang</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/023hj5876</institution-id><institution>Dalian University of Technology</institution></institution-wrap><country>China</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.12.27.522019">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.12.27.522019v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Caigang Liu as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) The authors should employ siRNA against ClpP to see if they can abrogate the biological effects of the drug combination.</p><p>2) Some cell viability assay experiments and Western experiments seem odd and therefore need to be re-conducted.</p><p>3) Possible toxicity issues should be discussed and elaborated in the main text.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Below are some specific points for the manuscript:</p><p>1. The cell viability curves for CAMA-1 seem a little odd. This experiment needs to be reconducted and amended.</p><p>2. Scale bars are required for Figure 2A.</p><p>3. Figure 3, Figure Legend, 'Viability', the first letter should always be capitalized and kept consistent in all figures.</p><p>4. Figure 4A-B, the bands for CHOP and ATF4 as well as a few others seem odd. This should be fixed.</p><p>5. Figure 4, ONCO201 (5uM/10uM), the authors need to quantify the bands to determine if the biological effects are dose dependent.</p><p>6. Supplemental Figure 2, scale bars are required.</p><p>7. Supplemental Figure 3, the bands for p-Foxo3a seem odd. This should be fixed.</p><p>8. References should be numbered and properly cited.</p><p>9. Again, some Western experiments should be reconducted and fixed as mentioned above. This is mandatory.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. It would be nice to see whether you can abrogate the effects of the combination with siRNA against ClpP. That would strengthen the mechanistic point you make.</p><p>2. Please check in Figure 4 whether you show the Î² actin corresponding to all your blots.</p><p>3. A reflection on possible toxicity should be considered to be included in the Discussion section.</p><p>4. Please consider moving statements of interpretation of your data from the Results section to the Discussion section.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85898.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Reviewer #1 (Recommendations for the authors):</p><p>Below are some specific points for the manuscript:</p><p>1. The cell viability curves for CAMA-1 seem a little odd. This experiment needs to be reconducted and amended.</p></disp-quote><p>We thank the reviewer for this valuable suggestion. Accordingly, we reconducted the dose response assays of CAMA-1, MCF7, and T47D everolimus sensitive and resistant cells with modified concentrations of everolimus that included lower doses (0-100nM) (Figure 1A). This figure has been updated in the manuscript.</p><disp-quote content-type="editor-comment"><p>2. Scale bars are required for Figure 2A.</p></disp-quote><p>We thank the reviewer for pointing out the low visibility of the scale bars in Figure 2A. We increased the resolution, thickness of the scale bars, and the font of letters and numbers and updated the images (Figure 2A).</p><disp-quote content-type="editor-comment"><p>3. Figure 3, Figure Legend, 'Viability', the first letter should always be capitalized and kept consistent in all figures.</p></disp-quote><p>We thank the reviewer for bringing this to our attention. This has now been edited (Figure 3A and B).</p><disp-quote content-type="editor-comment"><p>4. Figure 4A-B, the bands for CHOP and ATF4 as well as a few others seem odd. This should be fixed.</p></disp-quote><p>We thank the reviewer for this useful comment. We repeated the Western blot experiments for TUFM, TFAM, BiP, ATF4, CHOP, and Î²-actin for all 6 cell lines and treatments, using the iBlot Dry Blotting system (Invitrogen) for protein transfer on PVDF membrane to increase transfer efficiency for higher resolution figures. In addition, a different antibody was used for CHOP (CHOP Polyclonal Antibody Cat#15204-1-AP, RRID:AB_2292610, Proteintech) (Figure 4A and B). We believe these figures have increased resolution and have updated them in the manuscript.</p><disp-quote content-type="editor-comment"><p>5. Figure 4, ONCO201 (5uM/10uM), the authors need to quantify the bands to determine if the biological effects are dose dependent.</p></disp-quote><p>We thank the reviewer for this valuable suggestion. We performed quantitation of TUFM, TFAM, BiP, ATF4 and CHOP using ImageJ analysis. Protein expression levels were normalized to Î²-actin (Figure 4A).</p><disp-quote content-type="editor-comment"><p>6. Supplemental Figure 2, scale bars are required.</p></disp-quote><p>We thank the reviewer for pointing out the missing scale bars in Supplemental Figure 2. This has now been edited. (Figure 3âfigure supplement 1).</p><disp-quote content-type="editor-comment"><p>7. Supplemental Figure 3, the bands for p-Foxo3a seem odd. This should be fixed.</p></disp-quote><p>We thank the reviewer for this useful comment. Similar to Comment 4, we reconducted the Western blot experiments for pAKT, AKT, pERK, ERK, pFoxO3a, FoxO3a, pS6, S6, TRAIL and Î²-actin for all 6 cell lines and treatments using the iBlot Dry Blotting system (Invitrogen) for protein transfer on PVDF membrane to increase transfer efficiency and resolution. This figure was updated in the manuscript. A different antibody was used for pFoxO3a (phospho-FoxO3a/Ser294 Antibody Cat#5538, RRID:AB_10696878, Cell Signaling) and TRAIL (TRAIL Monoclonal Antibody, 55B709.3 Cat# MA1-41027; RRID:AB_1087999, Thermo Fisher Scientific) (Figure 4âfigure supplement 1).</p><disp-quote content-type="editor-comment"><p>8. References should be numbered and properly cited.</p></disp-quote><p>We have followed Journal guidelines for references.</p><disp-quote content-type="editor-comment"><p>9. Again, some Western experiments should be reconducted and fixed as mentioned above. This is mandatory.</p></disp-quote><p>We thank the reviewer for addressing this point. We reconducted the Western blot experiments for TUFM, TFAM, BiP, ATF4, CHOP, and Î²-actin for all 6 cell lines and treatments for Figure 4A and 4B, as well as the experiments for pAKT, AKT, pERK, ERK, pFoxO3a, FoxO3a, pS6, S6, TRAIL and Î²-actin for all 6 cell lines and treatments for Figure 4âfigure supplement 1.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. It would be nice to see whether you can abrogate the effects of the combination with siRNA against ClpP. That would strengthen the mechanistic point you make.</p></disp-quote><p>We thank the reviewer for this suggestion. It has been previously reported in breast cancer that the mechanism of ONC201/TIC10 action involves binding and activation of ClpP through multiple silencing experiments (Graves et al., 2019; Greer et al., 2022) Our study is unique in the discovery that this therapy is effective in advanced ER+ breast cancer cells resistant to everolimus, a common standard of care drug used in this patient population. We show that ONC201/TIC10 has an increased therapeutic response in everolimus resistant cells compared to cancer cells sensitive to this therapy and detail the specific pathway components driving this response. Our study is the first to describe that ONC201/TIC10 could be used as an add-on treatment after mTOR therapy progression.</p><p>We also show that ONC201/TIC10 causes enhanced mitochondrial dysfunction, including suppression of mitochondrial proteins, oxidative phosphorylation inhibition and activation of stress response in everolimus resistant cells. In addition to the prior publication of the proposed knockdown studies (Greer et al., 2022; Jacques et al., 2020; Graves et al., 2019; Ishizawa et al. 2019), the siRNA knockdown methodology has limitations in our model system based on the duration of the siRNA-induced knockdown, as the 3-diminsional assays are measured over 3-4 weeks, and a transient effect from siRNA may not be sufficient over the duration of the experiment.</p><p>We have amended the manuscript to reference the previously established findings which describe how knockdown of ClpP abrogates the biological effects of ONC201/TIC10 (Discussion line 251, and references listed). We thank the reviewer for this suggestion, as it strengthens the link between drug and mechanism.</p><p>Lastly, for everolimus, the mechanism of action is well-known (Faivre et al., 2006; Law et al., 2006; Mita et al., 2003). Everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. As everolimus, an mTOR inhibitor, does not target ClpP (but targets mTOR signaling), the ClpP knockdown is not relevant for this drugâs mechanism. We have included this information in the manuscript for clarity.</p><p>Introduction section, line 34</p><p>âEverolimus, an analog of rapamycin, binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that inhibits the activation of mTOR, a key regulatory kinase (Faivre et al., 2006; Law et al., 2006; Mita et al., 2003).â</p><p>Discussion section, line 251</p><p>âMechanistically, ONC201/TIC10 has been shown to directly activate ClpP, through various genetic and biochemical studies (Greer et al., 2022; Jacques et al., 2020; Graves et al., 2019; Ishizawa et al. 2019). In breast cancer, silencing of ClpP using siRNA or CRISPR/Cas9 System confirmed the ClpP-dependent effects of ONC201/TIC10 (Graves et al., 2019; Greer et al., 2022). Based on these established findings, we detail the specific pathway components driving the therapeutic response of ONC201/TIC10 in everolimus sensitive and resistant cells.â</p><p>References added:</p><p>Faivre, S., Kroemer, G., and Raymond, E. (2006). Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5, 671-688.</p><p>Graves, P.R., Aponte-Collazo, L.J., Fennell, E.M.J., Graves, A.C., Hale, A.E., Dicheva, N., Herring, L.E., Gilbert, T.S.K., East, M.P., McDonald, I.M., et al. (2019). Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues. ACS Chem Biol 14, 1020-1029.</p><p>Greer, Y.E., Hernandez, L., Fennell, E.M.J., Kundu, M., Voeller, D., Chari, R., Gilbert, S.F., Gilbert, T.S.K., Ratnayake, S., Tang, B., et al. (2022). Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis. Cancer Res Commun 2, 1144-1161.</p><p>Ishizawa, J., Zarabi, S.F., Davis, R.E., Halgas, O., Nii, T., Jitkova, Y., Zhao, R., St-Germain, J., Heese, L.E., Egan, G., et al. (2019). Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell 35, 721-737 e729.</p><p>Jacques, S., van der Sloot, A.M., C, C.H., Coulombe-Huntington, J., Tsao, S., Tollis, S., Bertomeu, T., Culp, E.J., Pallant, D., Cook, M.A., et al. (2020). Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development. Genetics 214, 1103-1120.</p><p>Law, M., Forrester, E., Chytil, A., Corsino, P., Green, G., Davis, B., Rowe, T., and Law, B. (2006). Rapamycin disrupts cyclin/cyclindependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res 66, 1070-1080.</p><p>Mita, M.M., Mita, A., and Rowinsky, E.K. (2003). Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 4, 126-137.</p><disp-quote content-type="editor-comment"><p>2. Please check in Figure 4 whether you show the Î² actin corresponding to all your blots.</p></disp-quote><p>We thank the reviewer for the suggestion. We included images for all Î²-actin (Figure 4A and B).</p><disp-quote content-type="editor-comment"><p>3. A reflection on possible toxicity should be considered to be included in the Discussion section.</p></disp-quote><p>We thank the reviewer for this useful comment. We included a statement on possible toxicity in Discussion (Discussion section, line 301).</p><p>âBased on the initial preclinical and clinical testing of ONC201/TIC10 that demonstrated benefit with a benign clinical profile, ONC201/TIC10 is being further evaluated as single agent or in combination with other cancer therapies for various tumor types (Prabhu et al., 2020). Combination of ONC201/TIC10 with everolimus has been tested in an in vivo prostate model and was well tolerated, with no additional toxicity (Lev et al., 2018).â</p><disp-quote content-type="editor-comment"><p>4. Please consider moving statements of interpretation of your data from the Results section to the Discussion section.</p></disp-quote><p>We thank the reviewer for this remark. We updated the Results section and Discussion section accordingly.</p><p>Results section, line 171-172 moved to Discussion section, line 268-270</p><p>âThis result suggests that in the sensitive cells, everolimus alleviates endoplasmic reticulum stress through the activation of different cell death mechanisms.â</p><p>Results section, line 187-188 moved to Discussion section, line 272-274</p><p>âFurthermore, Western blot analysis and gene expression data confirm that the observed activity of ONC201/TIC10 is via induction of mitochondrial stress rather than ERK/AKT inactivation.â</p><p>Results section, line 216-218 moved to Discussion section, line 234-236</p><p>âOur results show that non-responsive tumors continued to proliferate after everolimus treatment by utilizing oxidative phosphorylation pathway to fuel the growth of tumor cells and is consistent with the findings from the resistant cell lines, supporting that ONC201/TIC10 and modulation of mitochondrial function is effective in drug resistant cancer cells.â</p></body></sub-article></article>